| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | Biologics | Digestive System | ||
IND Submission example | IND | — | Subscribe to access the data. | Biologics | Digestive System | ||
IND Submission example | IND | — | Subscribe to access the data. | Biologics | Digestive System |
Recent Updates
Recently added Catalysts
Palisade Bio, Inc.$1.99
+0.07 (+3.59%)
D 31Pipeline Score Overvalued Biotech · Clinical
Market Cap
338.48 M
EPS
-1.07
P/E Ratio
-
Value Trade
6.47 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
6.00 M
Operating CF
-3.89 M
Total Assets
133.31 M
Total Liabilities
5.95 M
Equity
127.36 M
D/E Ratio
12,345
8.33 %
Week
-30.36 %
1 Month
17.47 %
3 Month
-16.67 %
6 Month
-99.93 %
5 Year
-100 %
All Time
Cash Data
Cash Position
132.63 M
Monthly Burn
1.30 M
Runway
100 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
42.29 K
52 Week Range
0.53 - 2.86
% held by Insiders
3.83 %
% held by Institutions
91.1 %
Enterprise Value
205.85 M
Total Shares
165.95 M
Short %
22.44 %
Float Shares
164.96 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Palisade Bio, Inc.
683Total events
5Upcoming
98Tier-1 (high impact)
2010 – 2028Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆R&D DayPresentation
Subscribe to view catalyst details
TBD
▲First Patient DosedPALI-2108Trial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | PALI-2108 | IND Submission | IND | — | – | – | – |
2026-06-30 | PALI-2108 | IND Submission | IND | — | – | – | – |
2026-06-30 | PALI-2108 | IND Submission | IND | — | – | – | – |
Drug Pipeline Intelligence
D31
Pipeline Score $134M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.4x
rNPV / MCap Top 40%
Micro Cap (rank 549 of 913)
Percentile RankPalisade Bio, Inc. faces pipeline headwinds (31/100), with $334M risk-adjusted pipeline value, led by PALI-2108 in Fibrostenotic Crohn's Disease (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PALI-2108 Small molecule | Fibrostenotic Crohn's Disease | Phase 1 | NCT07428096 | 8% | $188M | ACTIVE NOT_RECRUITING | 6 | SLOW | F (18) | Mar 15, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PALI-2108 | fibrostenotic Crohn’s disease | — | 2026-06-09 | positive results in a Phase 1a and two Phase 1b clinical trials Read More | Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium Read More | |
PALI-2108 | fibrostenotic Crohn’s disease | — | 2026-06-09 | positive results in a Phase 1a and two Phase 1b clinical trials Read More | Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium Read More | |
PALI-2108 | fibrostenotic Crohn’s disease | — | 2026-06-09 | positive results in a Phase 1a and two Phase 1b clinical trials Read More | Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PALI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PALI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PALIPalisade Bio to Participate in the Leerink Partners Therapeutics Forum
Palisade Bio, Inc. will participate in the Leerink Partners Therapeutics Forum on July 14-15, 2026, in Boston. CEO JD Finley and CMO Dr. Mitchell Jones will engage in one-on-one meetings with investors to discuss the clinical development of PALI-2108, a PDE4 inhibitor prodrug. The company is advancing towards Phase 2 studies for inflammatory bowel diseases.
Read more →PALI▲ +18%on this news
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
Palisade Bio has received FDA clearance for its IND application for PALI-2108, allowing the initiation of the ASCENTRA-UC Phase 2 trial in ulcerative colitis. The trial will enroll up to 204 patients across North America and Europe, with results expected in late 2027. This marks a significant milestone for the company's inflammatory bowel disease portfolio.
Read more →PALI▲ +6%on this news
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
Palisade Bio has appointed Robert Baltera and Jordan Zwick to its Board of Directors, enhancing its leadership team with extensive biopharmaceutical expertise. The company is progressing PALI-2108, a PDE4 inhibitor prodrug, toward Phase 2 clinical studies following encouraging results from earlier trials. This strategic move aims to strengthen the company's growth and development in addressing inflammatory bowel diseases.
Read more →PALIPalisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
Palisade Bio will present on PALI-2108, a PDE4 inhibitor prodrug, at the NYAS symposium. The presentation will address the unmet needs in treating fibrostenotic Crohn's disease and discuss preclinical findings supporting the drug's potential. PALI-2108 has shown promise in early clinical trials, and the company is moving towards Phase 2 studies.
Read more →PALIPalisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
Palisade Bio will present at the NYAS symposium on the potential of PALI-2108 for treating fibrostenotic Crohn's disease. The presentation will cover the unmet medical needs in this area and the scientific rationale behind using a locally bioactivated PDE4 inhibitor. PALI-2108 has shown promise in early clinical trials, advancing towards Phase 2 studies.
Read more →PALIPalisade Bio to Participate in the Jefferies Global Healthcare Conference
Palisade Bio, Inc. is set to present at the Jefferies Global Healthcare Conference from June 2-4, 2026, with a scheduled presentation on June 4. CEO JD Finley and CMO Dr. Mitchell Jones will lead the discussion, covering the company's innovative oral PDE4 inhibitor, PALI-2108, which shows promise in treating inflammatory and fibrotic diseases. The firm is moving forward to Phase 2 studies after positive outcomes in earlier clinical trials for ulcerative colitis and Crohn’s disease. Management will also hold one-on-one meetings with investors during the conference.
Read more →PALIPalisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Palisade Bio reported its first quarter 2026 financial results, highlighting the progress of its lead program, PALI-2108, a PDE4 inhibitor prodrug for inflammatory bowel disease. The company plans to initiate Phase 2 trials for ulcerative colitis and Crohn's disease in 2026, supported by a strong financial position. Recent data indicate sustained efficacy and safety of PALI-2108, reinforcing its potential as a treatment option.
Read more →PALIPalisade Bio, Inc. Condensed Consolidated St ateme nts of Cash Flows (Unaudited) (in thousands) Three Months Ended
Palisade Bio, Inc. reported its first quarter 2026 financial results and highlighted significant progress in its lead program, PALI-2108, a PDE4 inhibitor prodrug aimed at treating inflammatory bowel diseases. Following positive Phase 1 trial data, the company is advancing towards Phase 2 studies for Ulcerative Colitis and Crohn's disease, with expected trial initiations in 2026. Financially, the company maintains a robust balance sheet, allowing it to fund its clinical endeavors through the next crucial milestones.
Read more →PALI▼ -7.5%on this news
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Palisade Bio presented additional Phase 1a/b data for PALI-2108, highlighting its potential as a once-daily oral therapy for ulcerative colitis. The findings indicate sustained active metabolite exposure above the IC90 threshold, supporting continuous target inhibition. The data also show significant improvements in clinical and histologic outcomes, reinforcing the drug's localized pharmacologic activity.
Read more →PALIPalisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
Palisade Bio announced that its lead program, PALI-2108, will be presented at Digestive Disease Week 2026. The poster presentation will showcase data on the drug's effectiveness in treating ulcerative colitis. The event will take place in Chicago from May 2-5, 2026, where the company will engage with experts and investors.
Read more →PALIPalisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Palisade Bio, Inc. will present at the Needham & Co. 25th Annual Healthcare Conference on April 16, 2026. CEO JD Finley and CMO Dr. Mitchell Jones will discuss the company's advancements in oral PDE4 inhibitor prodrugs. The presentation will be accessible via webcast, and management will hold one-on-one meetings with investors.
Read more →PALIPalisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Palisade Bio, Inc. announced its participation in the Needham & Co. 25th Annual Healthcare Conference, with a presentation scheduled for April 16, 2026. The company will showcase its next-generation oral PDE4 inhibitor prodrugs, including its lead program PALI-2108, which is aimed at treating chronic inflammatory and fibrotic diseases. In addition to the presentation, Palisade management will engage in one-on-one meetings with registered investors, highlighting their commitment to transparency and communication.
Read more →PALI▼ -11%on this news
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
Palisade Bio reported positive topline results from its Phase 1b study of PALI-2108 in patients with fibrostenotic Crohn's disease. The study demonstrated favorable safety and tolerability, with no serious adverse events. Notably, 40% of participants achieved endoscopic response and remission, alongside significant reductions in inflammatory biomarkers. The company plans to advance PALI-2108 into a Phase 2 trial targeting moderate to severe Crohn's disease.
Read more →PALIPalisade Bio Announces Participation in Two Upcoming Investor Conferences
Palisade Bio, Inc. announced its participation in two investor conferences in March 2026, where management will present and hold meetings. The company is advancing its lead program, PALI-2108, which has shown a 100% clinical response in a Phase 1b trial for ulcerative colitis. Palisade is preparing for a Phase 2 study to further evaluate the drug's efficacy and safety.
Read more →PALIPalisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
Palisade Bio presented promising Phase 1b data for PALI-2108 at the ECCO 2026 congress. The data revealed rapid clinical responses and significant improvements in inflammatory markers within seven days of treatment. The localized action of the drug in the colon supports its targeted mechanism, with no serious adverse events reported. The company plans to advance PALI-2108 into Phase 2 studies.
Read more →PALIPalisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
Palisade Bio has appointed Dr. Bram Verstockt to its Clinical Advisory Board, enhancing its expertise in inflammatory bowel disease as it prepares for Phase 2 development of PALI-2108. The company plans to submit an IND application for a Phase 2 study in ulcerative colitis in the first half of 2026. PALI-2108 has shown a 100% clinical response in a Phase 1b trial, indicating strong potential for treating inflammatory bowel diseases.
Read more →PALIPalisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
Palisade Bio, Inc. will participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026. CEO JD Finley and CMO Dr. Mitchell Jones will engage in a fireside chat, discussing the company's innovative PDE4 inhibitor, PALI-2108, which has shown a 100% clinical response in a Phase 1b trial. The company is moving towards a Phase 2 study to further evaluate the drug's efficacy.
Read more →PALI▼ -5.1%on this newsshared move
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Palisade Bio, Inc. will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. CEO JD Finley and CMO Dr. Mitchell Jones will discuss the company's lead program, PALI-2108, which has shown promising results in a Phase 1b trial for ulcerative colitis. The presentation will be accessible via a live webcast.
Read more →PALIPalisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
Palisade Bio has appointed renowned IBD experts Laurent Peyrin-Biroulet and David T. Rubin to its Clinical Advisory Board. Their expertise will guide the development of PALI-2108, an oral PDE4 inhibitor prodrug, as it progresses toward Phase 2 trials for ulcerative colitis and fibrostenotic Crohn's disease. The company plans to submit an IND for Phase 2 UC trials in early 2026.
Read more →PALI▲ +13.9%on this news
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
Palisade Bio announced that two abstracts on its lead program, PALI-2108, have been selected for poster presentations at prominent inflammatory bowel disease conferences in early 2026. The presentations will focus on the drug's gut-targeted PDE4B inhibition and its Phase 1a findings in ulcerative colitis. The company aims to engage with the global IBD community to discuss these promising results.
Read more →PALI▲ +5.2%on this news
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
Palisade Bio announced a strategic equity investment of up to $500,000 from the Crohn's & Colitis Foundation's IBD Ventures program to support the development of PALI-2108. This PDE4 inhibitor targets ulcerative colitis and fibrostenotic Crohn's disease, addressing significant unmet needs. The investment underscores the potential of PALI-2108, which has shown promising results in early clinical trials.
Read more →PALI▲ +5.2%on this newsshared move
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
Palisade Bio announced a strategic equity investment of up to $500,000 from the Crohn’s & Colitis Foundation to advance PALI-2108, a PDE4 inhibitor targeting ulcerative colitis and fibrostenotic Crohn’s disease. The investment supports ongoing clinical studies, with promising results reported in earlier phases. PALI-2108 aims to address significant unmet needs in these conditions.
Read more →PALIPalisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
Palisade Bio has received a Japanese patent for PALI-2108, a PDE4 inhibitor aimed at treating ulcerative colitis and fibrostenotic Crohn's disease. This patent, which extends into 2041, enhances the company's intellectual property for its innovative drug. PALI-2108 has completed Phase 1 studies and is set for Phase 2 IND submission in early 2026.
Read more →PALI▼ -7.7%on this news
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
Palisade Bio has appointed Dr. James Izanec as Vice President of Clinical Development. Dr. Izanec, a seasoned gastroenterologist, brings over 20 years of experience in clinical trials, particularly in immunology and gastroenterology. His leadership is expected to significantly impact the development of PALI-2108, a promising treatment for ulcerative colitis and Crohn's disease. The company is preparing for a Phase 2 clinical study.
Read more →PALI▼ -5.7%on this news· ran to -18% by day 3
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
Palisade Bio, Inc. announced their participation in the Piper Sandler 37th Annual Healthcare Conference, featuring a live webcast fireside chat with CEO JD Finley and CMO Dr. Mitchell Jones. The company is focusing on advancing PALI-2108, a new oral PDE4 inhibitor prodrug aimed at treating inflammatory and fibrotic diseases, particularly moderate-to-severe Ulcerative Colitis and Fibrostenotic Crohn’s Disease. Recent Phase 1b trial results showed encouraging outcomes for PALI-2108, prompting preparations for a Phase 2 clinical study to assess its effectiveness and safety further.
Read more →PALI▲ +11.4%on this news· ran to +28% by day 1
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
Palisade Bio has appointed Sharon Skare as Vice President, Global Head of Clinical Operations. With over 24 years of experience, she will lead the advancement of PALI-2108, a therapy targeting ulcerative colitis and Crohn's disease. The company plans to submit an IND for Phase 2 studies in the first half of 2026, building on positive Phase 1 data.
Read more →PALI▲ +6.9%on this news
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
Palisade Bio has initiated dosing for the first patients in its Phase 1b study of PALI-2108, a novel PDE4 inhibitor prodrug aimed at treating fibrostenotic Crohn's disease. This study is significant as it targets a condition with no approved therapies. Topline safety and pharmacokinetic data are expected in Q1 2026, with plans for a Phase 2 IND submission in H1 2026.
Read more →PALI▲ +6.9%on this newsshared move
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
Palisade Bio has initiated dosing of the first patients in its Phase 1b study for PALI-2108, a novel PDE4 inhibitor prodrug aimed at treating fibrostenotic Crohn's disease. This study will assess the drug's safety, pharmacokinetics, and pharmacodynamics. Topline results are anticipated by Q1 2026, with further development planned for ulcerative colitis.
Read more →PALI▼ -7.5%on this news
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
Palisade Bio has received a Canadian patent for its lead product candidate PALI-2108, a PDE4 inhibitor aimed at treating fibrostenotic Crohn's disease and ulcerative colitis. The patent secures composition-of-matter protection until May 2041. The company is progressing with clinical trials, with patient dosing for a Phase 1b study expected in late 2025.
Read more →PALIPalisade Bio Announces Cancellation of Special Meeting of Stockholders
Palisade Bio has canceled its special meeting of stockholders originally scheduled for October 10, 2025, due to insufficient proxies to meet quorum requirements. This meeting was previously adjourned without any business conducted. The company will withdraw the proposals outlined in its proxy statement filed on August 18, 2025.
Read more →PALI▼ -5.9%on this news· ran to +18% by day 3
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
Palisade Bio has successfully closed a $138 million public offering, including the full exercise of the over-allotment option. The proceeds will be utilized to advance the Phase 2 clinical development of PALI-2108, a novel treatment for ulcerative colitis. The offering was well-received, reflecting investor confidence in the company's potential.
Read more →PALI▲ +52.4%on this news· ran to +122% by day 3shared move
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock
Palisade Bio has announced the pricing of an upsized underwritten public offering of 171,440,559 shares at $0.70 per share, aiming to raise approximately $120 million. The offering is expected to close around October 2, 2025, pending customary closing conditions. Ladenburg Thalmann & Co. Inc. is managing the offering, which includes an option for underwriters to purchase additional shares.
Read more →PALIPalisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
Palisade Bio announced the adjournment of its special meeting of stockholders due to insufficient quorum, as less than one-third of the outstanding shares were present. The meeting will reconvene on October 10, 2025, allowing more time for stockholders to vote on proposals. The company continues to solicit votes and has engaged a proxy solicitor to assist in achieving the required quorum.
Read more →PALIPalisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data
Palisade Bio reported positive Phase 1b clinical data for PALI-2108, showing a 100% clinical response in ulcerative colitis patients without serious adverse events. The study indicated strong safety and promising efficacy signals, with biomarker analyses supporting its potential in treating fibrotic conditions. Patient dosing for the Phase 1b study in fibrostenotic Crohn's disease is expected to begin in 2025.
Read more →PALIPalisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)
Palisade Bio has received Health Canada clearance for a Phase 1b trial of PALI-2108, a novel treatment for fibrostenotic Crohn's disease. This first dual-acting anti-inflammatory and anti-fibrotic candidate aims to address a significant unmet need, as current therapies do not effectively alter the disease process. Patient dosing is expected to start in H2 2025, with topline data anticipated in Q1 2026.
Read more →PALIPalisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)
Palisade Bio has received Health Canada clearance for a Phase 1b trial of PALI-2108, a dual-acting anti-inflammatory and anti-fibrotic therapy for fibrostenotic Crohn's disease (FSCD). The trial will begin patient dosing in H2 2025, with topline data expected in Q1 2026. This marks a significant milestone as there are currently no approved therapies for FSCD.
Read more →PALI▼ -8.5%on this news
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
Palisade Bio has released a Virtual Investor KOL Connect segment featuring Dr. Brian Feagan, a leading expert in Fibrostenotic Crohn's Disease (FSCD). The discussion emphasizes the urgent need for better treatment options for FSCD and presents PALI-2108 as a potential leader among new therapies targeting Inflammatory Bowel Diseases (IBD). Dr. Feagan highlights the drawbacks of current therapies and explains how PALI-2108's localized approach could reduce side effects while enhancing therapeutic effects.
Read more →PALI▼ -12.2%on this news
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
Palisade Bio reported successful results from its Phase 1b clinical study of PALI-2108 in patients with moderate-to-severe ulcerative colitis, achieving a 100% clinical response rate. The treatment showed strong biomarker and histological improvements without serious adverse events. The company plans to advance towards an IND submission for a Phase 2 study by the first half of 2026. The drug's local bioactivation and extended half-life suggest it could become a leading oral therapy for ulcerative colitis and potentially for fibrostenotic Crohn's disease as well.
Read more →PALIPalisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
Palisade Bio has received a Notice of Allowance from China's National Intellectual Property Administration for a patent covering PALI-2108, a novel PDE4 inhibitor. PALI-2108 is designed to treat fibrostenotic Crohn's disease and ulcerative colitis, addressing significant unmet medical needs. This allowed patent, extending into 2045, supports the company's objectives in one of the world's largest pharmaceutical markets. The company is currently conducting a Phase 1b/2a clinical trial for PALI-2108, with several upcoming clinical milestones anticipated in the next 12-18 months.
Read more →PALI▼ -9%on this news
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
Palisade Bio, Inc. announced the exercise of existing warrants, raising approximately $3.9 million. The warrants, originally issued at higher prices, were exercised at a reduced price of $0.9047 per share. The funds will be used for working capital and general corporate purposes. The company will also issue new Replacement Warrants to investors.
Read more →PALI▲ +41.9%on this newsshared move
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million Carlsbad, CA
Palisade Bio, Inc. announced the exercise of warrants resulting in approximately $3.9 million in gross proceeds. This transaction involves the exercise of existing warrants by several accredited investors at an adjusted price, giving Palisade additional capital for corporate purposes. Future operations and product development hinge on the company's ability to effectively conduct clinical trials and secure additional financing. Additionally, the exercise of these warrants introduces Replacement Warrants for investors, potentially expanding investor interest.
Read more →PALI▼ -9.2%on this news· ran to +29% by day 1shared move
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Palisade Bio, a clinical-stage biopharmaceutical company, announced CEO JD Finley's participation in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. During the event, Finley discussed his dedication to the company and its therapeutic programs. The video webcast is now available for viewing on the company's website.
Read more →PALI▼ -9.2%on this news· ran to +29% by day 1shared move
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Palisade Bio, a clinical-stage biopharmaceutical company, recently participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. CEO JD Finley shared his journey and expressed his strong commitment to the company's development of therapeutics for autoimmune, inflammatory, and fibrotic diseases. The event is accessible through video webcasts on the company's investor portal and is intended to enhance investor engagement and awareness of Palisade's innovative programs.
Read more →PALI▲ +5.4%on this news
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors
Palisade Bio has appointed Emil Chuang to its Board of Directors, enhancing its clinical strategy in treating Fibrostenotic Crohn's Disease and Ulcerative Colitis. Chuang, a seasoned pediatric gastroenterologist, has nearly 25 years of experience in the pharmaceutical industry and has contributed to successful drug development programs. His insights are expected to advance Palisade's pipeline significantly.
Read more →PALI▲ +5.4%on this newsshared move
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors Veteran clinical leader with successful track record and experience to help guide the Company's clinical strategy in Fibrostenotic Crohn's Disease
Palisade Bio, Inc. has appointed Emil Chuang, a seasoned pediatric gastroenterologist, to its Board of Directors, aiming to enhance its clinical strategy in treating Fibrostenotic Crohn's Disease and Ulcerative Colitis. Chuang brings nearly 25 years of pharmaceutical experience and has contributed significantly to drug development programs, including successful regulatory approvals. The company anticipates leveraging his expertise to advance their clinical programs and address unmet medical needs in the field of inflammatory bowel diseases. Chuang also emphasizes excitement about contributing to the company's pipeline and its potential impact on patient outcomes.
Read more →PALIPalisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
Palisade Bio announced positive topline results from its Phase 1 studies of PALI-2108, a PDE4 B/D inhibitor for fibrostenotic Crohn's disease and ulcerative colitis. The study met primary endpoints for safety, tolerability, and pharmacokinetics, showing no serious adverse events. The results support advancing to Phase 2 trials to evaluate efficacy in patients.
Read more →PALIPalisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
Palisade Bio announced positive topline results from its Phase 1 studies of PALI-2108, a novel targeted PDE4 B/D inhibitor for fibrostenotic Crohn’s disease and ulcerative colitis. The study achieved its primary endpoints of safety, tolerability, and pharmacokinetics, demonstrating no serious adverse events or notable risks. PALI-2108 is designed to deliver therapeutic concentrations specifically to the colon while minimizing systemic exposure. Following these results, the company plans to advance to Phase 2 clinical trials to further assess the drug's efficacy and safety in the target populations.
Read more →PALI▲ +6.1%on this news
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
Palisade Bio has presented positive preclinical data for PALI-2108, a colon-specific PDE4 inhibitor, at Digestive Disease Week 2025. The data highlights its efficacy in treating ulcerative colitis by effectively modulating inflammatory pathways and demonstrating improvements in disease parameters in a mouse model. With a favorable safety profile reported in ongoing Phase 1a/b studies, PALI-2108 is positioned as a promising therapy for inflammatory bowel diseases. Topline data from the Phase 1a study is expected by the end of May 2025.
Read more →PALIPalisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
Palisade Bio, Inc. has announced it will present at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit. The oral presentation, titled 'Improving Patient Subtyping with AI-Driven Insights', aims to address IBD heterogeneity and efficacy issues. The summit will take place from May 13 to 15, 2025, in Boston, MA, where leading advancements in precision medicine will be explored. Palisade aims to enhance patient outcomes using their AI-driven insights. However, the company acknowledges challenges in clinical development and the need for additional funding.
Read more →PALIPalisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
Palisade Bio has completed dosing in the Phase 1a portion of its ongoing Phase 1a/b study of PALI-2108 for Ulcerative Colitis (UC). Preliminary results demonstrate no serious adverse events or notable treatment-emergent adverse events, confirming the drug's safety and tolerability. The company plans to screen and dose participants for the Phase 1b cohort, with topline data expected in the first half of 2025. This study represents an important step in evaluating PALI-2108 as a potential treatment option for patients with UC.
Read more →PALI▲ +9%on this news
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
Palisade Bio, Inc. has begun dosing its first ulcerative colitis patient in the Phase 1a/b study of PALI-2108. Preliminary results from single and multiple ascending dose cohorts show good safety and tolerability, with no serious adverse events encountered so far. The company anticipates reporting topline data in the first half of 2025 and emphasizes the significance of their transition from healthy volunteers to actual UC patients. These steps mark critical progress for the drug, which is a new chemical entity focused on treating inflammatory diseases.
Read more →PALI▲ +11.7%on this newsshared move
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
Palisade Bio, Inc. (Nasdaq: PALI) announced that two abstracts related to its lead drug candidate, PALI-2108, have been selected for presentation at the upcoming Digestive Disease Week (DDW) 2025. This includes a Poster of Distinction which highlights the drug's potential efficacy in treating ulcerative colitis. The presentations will be made during sessions focused on gastrointestinal disorders. While the recognition is a positive milestone for Palisade, the company still faces risks associated with clinical development and funding.
Read more →PALIPalisade Bio Participates in Virtual Investor “What This Means” Segment
Palisade Bio has released a Virtual Investor segment featuring Dr. Joerg Heyer, who discussed positive preclinical data for their lead product candidate, PALI-2108, aimed at treating Ulcerative Colitis. This data was recently presented at the 2025 Crohn’s and Colitis Congress. The company emphasizes its commitment to developing novel therapeutics for autoimmune and inflammatory diseases.
Read more →PALIPalisade Bio Participates in Virtual Investor “What This Means” Segment
Palisade Bio, Inc. participated in a Virtual Investor segment where Dr. Joerg Heyer discussed the positive preclinical data for their lead product candidate, PALI-2108, targeting ulcerative colitis. The data was presented at the 2025 Crohn's and Colitis Congress, indicating potential advancements in the company’s development pipeline. However, the company faces uncertainties regarding clinical development and regulatory approval, alongside the need for additional funding for future operations.
Read more →PALIPalisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
Palisade Bio, Inc. announced it has received CAD$1.39 million from Canada's SR&ED Tax Credit Program to reimburse development costs for PALI-2108, aimed at treating ulcerative colitis. The funding is part of a joint development plan with Giiant Pharma. The company is currently conducting a Phase 1a/b study, with topline data expected in the first half of 2025.
Read more →PALIPalisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
Palisade Bio, Inc. has announced the receipt of CAD$1.39 million in funding from Canada’s SR&ED Tax Credit Program to reimburse prior pre-clinical costs associated with PALI-2108, a drug aimed at treating ulcerative colitis. The funding, received through their partnership with Giiant Pharma, reinforces their development strategy for the compound. Currently, Palisade is conducting a Phase 1a/b clinical study, with topline data anticipated in the first half of 2025, which may provide insights into the drug's safety and efficacy. The company remains focused on advancing its therapeutic offerings for autoimmune and inflammatory diseases.
Read more →PALIPalisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference
Palisade Bio, Inc. participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference, where CEO JD Finley highlighted key reasons for investment interest in the company. The on-demand video webcast is now available for viewing. Palisade Bio focuses on developing novel therapeutics for autoimmune and fibrotic diseases, but faces challenges related to funding and clinical development risks.
Read more →PALIPalisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Palisade Bio, Inc. has participated in the Virtual Investor "Top 5 for '25" On-Demand Conference, where CEO JD Finley presented key reasons for investment interest. The company's focus is on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. The on-demand video presentation is now available for viewing. However, Palisade faces significant risks related to the clinical development and regulatory approval of its lead product, PALI-2108, alongside financial uncertainties requiring additional funding.
Read more →PALI▼ -7.2%on this news· ran to -18% by day 3
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio has presented positive preclinical data for PALI-2108, an oral PDE4 inhibitor prodrug targeting ulcerative colitis. The data revealed that PALI-2108 significantly reduced colitis symptoms in a mouse model without causing central nervous system toxicity. The company is advancing the drug into Phase 1a/b studies, expecting to report topline data in the first half of 2025. PALI-2108 has shown promising pharmacokinetics and a favorable safety profile in initial studies.
Read more →PALIPalisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
Palisade Bio, Inc. announced that its abstract has been accepted for a poster presentation at the upcoming Crohn's & Colitis Congress in February 2025. The presentation will highlight PALI-2108, a colon-specific PDE4B inhibitor prodrug, which has shown efficacy in reducing ulcerative colitis symptoms in preclinical models. This event marks a significant opportunity for the company to showcase its advancements in treating autoimmune diseases.
Read more →PALIPalisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
Palisade Bio, Inc. announced that its abstract has been accepted for a poster presentation at the upcoming Crohn’s & Colitis Congress, taking place from February 6-8, 2025, in San Francisco. The presentation will focus on PALI-2108, a colon-specific PDE4B inhibitor that has shown efficacy in reducing ulcerative colitis symptoms in a mouse model. The event represents an important opportunity for the company to showcase its innovative therapeutic approach to treating inflammatory diseases.
Read more →PALI▼ -5.3%on this news
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Palisade Bio, Inc. (Nasdaq: PALI) has announced that CEO JD Finley will present at the LIVE! with Webull Corporate Connect webinar on January 29, 2025. The company focuses on developing novel therapeutics for autoimmune and inflammatory diseases, aiming to transform the treatment landscape. This presentation will provide an opportunity for investors to learn more about Palisade's strategic direction and innovations in biopharmaceutical therapies.
Read more →PALI▼ -5.7%on this news· ran to -19% by day 3shared move
Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
Palisade Bio has successfully completed all five SAD cohorts of its Phase 1a/b trial for PALI-2108, an investigational treatment for ulcerative colitis. Preliminary data indicate that PALI-2108 was well-tolerated across all doses tested, with no serious adverse events reported. The trial will now advance to the Multiple Ascending Dose (MAD) cohorts, which will further evaluate the drug's safety and pharmacokinetics. The company expects to report topline data in the first half of 2025.
Read more →PALIPalisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Palisade Bio, a clinical-stage biopharmaceutical company, has announced the issuance of an equity grant to a new employee under its 2021 Inducement Plan. This grant involves an option to purchase 2,600 shares of common stock, with the exercise price matching the closing price on the grant date. The vesting of this option occurs quarterly over three years, contingent upon ongoing employment. This move reflects the company's strategy to attract top talent as it focuses on developing therapeutics for autoimmune and fibrotic diseases.
Read more →PALIPalisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
Palisade Bio has appointed Dr. Brian Feagan to its Clinical Advisory Board, recognizing his extensive experience in gastroenterology and clinical trials for Crohn's disease and ulcerative colitis. Dr. Feagan's expertise is expected to aid in the development of the company's novel therapeutic, PALI-2108, which aims to address tolerability issues in existing treatments. His background includes involvement in over 140 multi-center randomized controlled trials, making him a valuable asset for advancing clinical efficacy strategies.
Read more →PALI▼ -25%on this newsshared move
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
Palisade Bio, Inc. recently closed a public offering, generating approximately $5 million before deductions. The offering includes Class A and Class B Units, with warrants attached for prospective investors. Proceeds are intended to fund the company's Phase 1 clinical trial of PALI-2108 and support ongoing research and development efforts. The Securities and Exchange Commission had previously declared the registration statement effective, facilitating the offering. An underwriter option allows for additional shares if needed, indicating potential for further investment.
Read more →PALI▲ +68.6%on this newsshared move
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
Palisade Bio announced a public offering pricing of approximately $5 million, which aims to support its clinical and preclinical research activities, particularly the Phase 1 trial of PALI-2108. The offering consists of Class A and Class B units, containing common stock and warrants, priced at $1.525 and $1.5249 respectively. Ladenburg Thalmann & Co. is managing the offering, which is expected to close shortly pending customary conditions. The company also plans to reprice previously issued warrants as part of the offering process.
Read more →PALI▲ +68.6%on this newsshared move
CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules Carlsbad, CA
Palisade Bio, Inc. has announced the pricing of a public offering aimed at raising approximately $5 million. This offering includes Class A and Class B units, each comprising shares of common stock with accompanying warrants. The net proceeds from this offering are intended to primarily fund the Phase 1 clinical trial of their therapeutic candidate PALI-2108, along with pre-clinical studies and other operational costs. The closing of the offering is anticipated for December 13, 2024, subject to customary conditions.
Read more →PALI▼ -5%on this news· ran to -26% by day 3
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects
Palisade Bio has announced preliminary results from its Phase 1 clinical study of PALI-2108, a potential treatment for moderate-to-severe Ulcerative Colitis. The initial data from three single ascending dose cohorts indicated that the drug was safe and well tolerated by participants, with no treatment-related adverse events reported. The study is designed to assess safety, tolerability, and pharmacokinetics, and it is proceeding to evaluate the effects of food on its pharmacokinetics in future cohorts. The company plans to report topline results in the first half of 2025.
Read more →PALIPalisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn’s Disease and Ulcerative Colitis (UC)
Palisade Bio announced promising preclinical results for PALI-2108, a local PDE4 inhibitor, at the 8th Annual Antifibrotic Drug Development Summit. The data indicates that PALI-2108 effectively engages key fibrotic pathways in fibrostenotic Crohn's disease, potentially offering a safer and more effective treatment compared to existing therapies. The company is currently evaluating PALI-2108 in a Phase 1 clinical study.
Read more →PALIPalisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
Palisade Bio has announced preclinical results for PALI-2108, a local PDE4 inhibitor prodrug, demonstrating its potential efficacy in treating fibrostenotic Crohn's disease. The findings reveal a dose-dependent impact on key fibrotic pathways and suggest that PALI-2108 may provide a safer and more effective option compared to existing therapies. The data will be presented at the 8th Annual Antifibrotic Drug Development Summit in Boston. The company is currently evaluating PALI-2108 in a Phase 1 study focused on safety and pharmacodynamics, with expected data in the first half of 2025.
Read more →PALI▲ +19.1%on this news
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit
Palisade Bio, Inc. announced that its Chief Medical Officer, Mitch Jones, MD, PhD, will present at the 8th Annual Antifibrotic Drug Development Summit from November 19-21, 2024, in Boston, MA. The presentation will cover advancements in fibrostenotic Crohn's Disease and the potential benefits of a localized PDE4 inhibitor prodrug. This summit gathers experts in antifibrotic drug development to discuss new research and treatment strategies. Palisade continues to focus on novel therapeutics for autoimmune and fibrotic diseases.
Read more →PALIPalisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108
Palisade Bio, Inc. (NASDAQ: PALI) reported its financial results for Q3 2024 and detailed progress on its lead program, PALI-2108, aimed at treating moderate-to-severe Ulcerative Colitis (UC). The company commenced patient enrollment and dosing in a Phase 1 clinical study, which is vital for understanding the drug's safety and efficacy. Financially, the company holds $8.0 million in cash, enough to sustain operations through early 2025, while recording a loss of $3.5 million for the quarter. Key milestones include expected topline data from the Phase 1 trial in the first half of 2025 and the initiation of further studies later that year.
Read more →PALIPalisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)
Palisade Bio has announced that it has successfully dosed its first subject in a Phase 1 clinical study of PALI-2108, a new PDE4 inhibitor prodrug. The study aims to evaluate the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers as well as in patients with moderate-to-severe ulcerative colitis. This marks a significant milestone as the company transitions into clinical stages, with topline data expected by mid-2025. The study is designed to gather comprehensive insights into the drug's effects through various evaluations and biomarker analyses.
Read more →PALI▼ -12.3%on this news
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio has announced positive results from two translational studies of its oral PDE4 inhibitor prodrug, PALI-2108, for treating ulcerative colitis. Data presented at the ACG 2024 Annual Scientific Meeting demonstrated effective bioactivation of PALI-2108 in stool samples, leading to significant TNFα inhibition. The company plans to initiate a Phase 1 clinical trial focusing on safety and pharmacokinetics, with preparations underway to begin patient dosing by the end of the year.
Read more →PALIPalisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting
Palisade Bio, Inc. announced that its abstract has been accepted for a poster presentation at the American College of Gastroenterology's 2024 Annual Scientific Meeting. The event will take place from October 25-30, 2024, in Philadelphia, PA. This opportunity allows Palisade to present its advancements in therapeutics for autoimmune and inflammatory diseases.
Read more →PALIPalisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting
Palisade Bio, Inc. announced that its abstract has been accepted for a poster presentation at the American College of Gastroenterology's 2024 Annual Scientific Meeting scheduled for October 25-30, 2024, in Philadelphia. The event is significant for professionals in the gastrointestinal field as it aims to educate about digestive disorders. Palisade Bio is concentrating on innovative therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, reflecting its focus on transforming treatment options.
Read more →PALIPalisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
Palisade Bio has received approval from Health Canada to initiate a Phase 1 clinical study for its lead program, PALI-2108, targeting ulcerative colitis (UC). This Phase 1 study will assess the safety, tolerability, and pharmacokinetics of PALI-2108 in a double-blind, placebo-controlled setting with healthy volunteers and UC patients. The drug aims to meet the medical needs of UC patients who currently face limited effective treatment options. Preparations for the trial are on track to commence by the end of the year.
Read more →PALI▼ -7.1%on this newsshared move
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
Palisade Bio, Inc. (Nasdaq: PALI) announced its participation in the 2024 Maxim Healthcare Virtual Summit, scheduled for October 15, 2024. The company's CEO, J.D. Finley, and CMO, Dr. Mitch Jones, will engage in a fireside chat, discussing advancements in therapeutics for autoimmune, inflammatory, and fibrotic diseases. The summit will feature presentations from various biotechnology and healthcare sector companies, promising insightful discussions.
Read more →PALI▼ -9.7%on this news
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio, Inc. has announced significant advancements in the launch of its Phase 1 clinical study for PALI-2108, a treatment for ulcerative colitis. Key milestones include the completion of safety studies and regulatory consultations, assisting in the progress towards clinical site initiation. The study aims to evaluate the safety and pharmacokinetics of PALI-2108 in both healthy volunteers and patients with ulcerative colitis, with the company maintaining confidence in commencing the trial by year-end. Moreover, Palisade is exploring patient enrichment strategies through advanced technology in biomarker identification.
Read more →PALIPalisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies
Palisade Bio announced its new corporate branding alongside a commitment to advancing its lead program, PALI-2108, for treating ulcerative colitis. The company has completed nonclinical safety studies and is preparing for Phase 1 clinical trials. Palisade is focused on developing targeted therapies for autoimmune, inflammatory, and fibrotic diseases, leveraging machine learning to enhance treatment efficacy. The new branding aims to reflect its vision and the company's dedication to meeting significant medical needs in these areas.
Read more →PALIPalisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification
Palisade Bio has announced significant findings regarding PDE4B expression as a potential biomarker for patient stratification in Ulcerative Colitis treatment. Data indicates that 70% of adult and 90% of pediatric patients exhibit elevated PDE4B levels. The company is advancing its lead candidate PALI-2108, an orally administered PDE4 inhibitor, with plans to begin a Phase 1 clinical trial before the end of the year. This advancement aims to enhance treatment personalization and efficacy for patients suffering from colitis.
Read more →PALIPalisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
Palisade Bio, Inc. reported its second quarter 2024 financial results, highlighting progress in the development of its lead candidate PALI-2108 for ulcerative colitis. Notable advancements include the completion of a GMP batch and positive preclinical data indicating safety and efficacy. The company has sufficient cash to support its operations through the first quarter of 2025 and plans to initiate a Phase 1 study by year-end. Additionally, the firm is expanding its intellectual property portfolio and developing a biomarker-based patient selection approach for better therapeutic targeting.
Read more →PALIPalisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
Palisade Bio announced the selection of a dose for its upcoming Phase 1 clinical trial of PALI-2108, focusing on patients with Ulcerative Colitis. The company has completed extensive preclinical studies, including pharmacokinetic modeling and safety evaluations, to determine the starting dose. The Phase 1 trial is anticipated to begin before the end of the year and will assess the safety, tolerability, and pharmacokinetics of PALI-2108 in both healthy volunteers and UC patients. The firm is optimistic about translating its findings into potential therapeutic advancements.
Read more →PALI▲ +11.7%on this news
Palisade Bio Participates in Virtual Investor “What this Means” Segment
Palisade Bio announced a Virtual Investor segment featuring Dr. Mitch Jones, discussing the successful microbiome study of PALI-2108. This study confirms the local bioactivation of the product candidate, which is intended for treating Ulcerative Colitis. The findings are significant as they pave the way for the planned Phase 1 clinical study.
Read more →PALI▲ +11.7%on this newsshared move
Palisade Bio Participates in Virtual Investor “What this Means” Segment
Palisade Bio, Inc. has participated in a Virtual Investor segment where Dr. Mitch Jones, the Chief Medical Officer, discussed positive findings from a recent microbiome study. This study confirmed the local bioactivation of their lead product candidate, PALI-2108, which is intended for the treatment of Ulcerative Colitis. The company is preparing for a planned Phase 1 human clinical study, which marks a significant step forward in their development of innovative therapies for autoimmune and inflammatory diseases.
Read more →PALI▼ -12.1%on this newsshared move
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
Palisade Bio has announced the successful completion of a microbiome study validating the presence of beta-glucuronidase enzymes across species, including in patients with ulcerative colitis. The findings support the ongoing development of PALI-2108, with plans to initiate a Phase 1 human clinical study for ulcerative colitis treatment by the end of 2024. This study provides further evidence for the bioactivation of the prodrug in the gastrointestinal tract, crucial for delivering its active ingredient effectively.
Read more →PALIHello world!
The article is a simple introductory post welcoming users to WordPress. It encourages users to edit or delete the default post and start creating their own content. There are no specific details or news related to the biopharma industry.
Read more →PALIPalisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108
Palisade Bio has announced that the European Patent Office is set to grant a patent for its lead product candidate PALI-2108, a drug aimed at treating moderate-to-severe Ulcerative Colitis. The patent includes claims for both PALI-2108 and its related program PALI-1908, indicating a strengthened intellectual property position for the company. PALI-2108 is expected to enter a Phase 1 clinical study by the end of 2024, showcasing its potential as a novel therapeutic option for patients with inflammatory bowel disease.
Read more →PALIPalisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
Palisade Bio has announced the successful completion of the first GMP manufacturing batch of its drug substance PALI-2108, aimed at treating moderate-to-severe ulcerative colitis. This milestone includes the formulation of enteric-coated tablets that have shown consistent drug release profiles. The company is preparing to initiate a Phase 1 clinical study of PALI-2108 by the end of the year, following positive outcomes from prior nonclinical studies. The partnership with Eurofins for GMP compliance further strengthens the development path for this therapeutic.
Read more →PALIPalisade Bio to Participate in the Virtual Investor Closing Bell Series
Palisade Bio, Inc. will participate in the Virtual Investor Closing Bell Series on June 26, 2024. The event will feature a corporate overview by CEO J.D. Finley and CMO Dr. Mitch Jones, allowing for live questions from investors. The presentation will be webcasted, with a replay available shortly after the event, emphasizing the company's commitment to investor communication and transparency.
Read more →PALIPalisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
Palisade Bio, Inc. has provided an update regarding its strategic collaboration with Strand Life Sciences, focusing on precision medicine for ulcerative colitis (UC). Significant progress has been made in identifying PDE4-related biomarkers that are linked to UC pathophysiology. The collaboration aims to refine patient stratification methods and enhance the development of tailored therapies for UC. Executives expressed commitment to innovation aimed at transforming UC treatments and improving patient outcomes.
Read more →PALIPalisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108
Palisade Bio, Inc. received a Notice of Allowance for a Canadian patent covering its lead product candidate, PALI-2108, a colon-specific PDE4 inhibitor aimed at treating ulcerative colitis. The company is set to begin Phase 1 human clinical studies for PALI-2108 before the end of 2024. In preclinical studies, PALI-2108 showed promising results, reducing disease activity in mouse models. This patent represents a significant step towards establishing a robust intellectual property portfolio for the drug.
Read more →PALIPalisade Bio to Present at the Virtual Investor Pitch Conference
Palisade Bio, Inc. has announced its participation in the Virtual Investor Pitch Conference scheduled for June 17, 2024. CEO J.D. Finley will provide a presentation highlighting the company's future milestones and will answer investor questions live. The event underscores Palisade's commitment to developing novel therapeutics for autoimmune and inflammatory diseases and aims to strengthen its relationship with investors. A live webcast of the presentation will be available on the company's website.
Read more →PALI▼ -7.5%on this news
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
Palisade Bio presented positive preclinical data for PALI-2108 at DDW 2024, showing its efficacy as a PDE4 inhibitor for ulcerative colitis (UC). The drug, which is orally administered and colon-specific, demonstrated a dose-dependent response in mouse models. The company plans to initiate Phase 1 clinical trials for PALI-2108 before the end of the year.
Read more →PALI▼ -7.5%on this newsshared move
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
Palisade Bio presented promising preclinical results for its lead product candidate, PALI-2108, at Digestive Disease Week 2024. The data highlighted that PALI-2108 achieved a dose-dependent efficacy response in DSS colitis mouse models, showing results comparable to apremilast but without systemic toxicity. The company plans to start a Phase 1 clinical study for ulcerative colitis treatment by the end of the year, aiming to address an unmet need for patients. The drug's design allows for local activation, potentially minimizing adverse effects commonly associated with similar therapies.
Read more →PALIPalisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Palisade Bio, Inc. reported its Q1 2024 financial results and a business update, highlighting progress towards a Phase 1 clinical study of its lead product candidate, PALI-2108, for Ulcerative Colitis. The company has secured enough funding through a $4.0 million private placement to carry its operations through 2025. Notable achievements include the successful completion of ex-vivo studies and the formation of a collaboration with Strand Life Sciences to enhance its bioinformatics capabilities. However, the company also reported an increased net loss compared to the previous year and a rise in R&D expenses due to the new asset development.
Read more →PALI▼ -6.6%on this news· ran to -21% by day 3
Palisade Bio Appoints Margery Fischbein to its Board of Directors
Palisade Bio has appointed Margery Fischbein to its Board of Directors. Fischbein brings extensive experience in healthcare investment banking and is expected to contribute significantly to the company's strategic goals. Her expertise will be instrumental in advancing Palisade's innovative approaches to treating autoimmune and inflammatory diseases, particularly ulcerative colitis.
Read more →PALI▼ -6.6%on this news· ran to -21% by day 3shared move
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Palisade Bio, Inc. has completed a private placement with an institutional investor, raising approximately $4 million through the sale of over 615,000 shares of common stock. The company plans to allocate the net proceeds towards the development of its lead therapeutic asset, PALI-2108, along with general corporate purposes. Additionally, the offering includes unregistered warrants for the purchase of more than 900,000 shares of common stock, highlighting investor interest in the company’s future growth.
Read more →PALI▼ -6.6%on this news· ran to -21% by day 3shared move
Palisade Bio Appoints Margery Fischbein to its Board of Directors Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transaction
Palisade Bio, Inc. has announced the appointment of Margery Fischbein to its Board of Directors. Fischbein brings extensive experience in healthcare investment banking and has held senior positions in various reputable firms. Her expertise in corporate finance and strategic alliances is expected to enhance Palisade's ability to advance its therapeutic pipeline, particularly in drug development for autoimmune diseases. Both Fischbein and Palisade's CEO expressed optimism about the strategic direction and innovations the company is pursuing in ulcerative colitis treatments.
Read more →PALIPalisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules Carlsbad, CA
Palisade Bio, Inc. has announced a definitive agreement for a private placement to sell 615,242 shares of common stock at a price of $6.5015 per share, expected to generate approximately $4 million before fees. The proceeds will be used for working capital and other corporate purposes. Additionally, the company will issue warrants for future purchases of common stock. The deal is set to close by May 6, 2024, pending customary conditions. This step signifies Palisade Bio's commitment to advancing its therapeutic developments for patients with complex diseases.
Read more →PALI▲ +17.4%on this news· ran to +40% by day 3shared move
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
Palisade Bio has announced positive results from a study evaluating its lead product candidate, PALI-2108, showing its effective anti-inflammatory properties. The drug, aimed at treating Ulcerative Colitis, outperformed the approved therapy apremilast in terms of efficacy in inhibiting TNF-α production. The company is set to begin Phase 1 human clinical trials before the end of the year, indicating strong progress in developing this novel therapeutic option. Overall, the findings highlight PALI-2108's potential in addressing inflammatory bowel disease.
Read more →PALI▲ +20.1%on this news
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
Palisade Bio has entered into a strategic collaboration with Strand Life Sciences to enhance its precision medicine approach for ulcerative colitis (UC) therapy. The partnership grants Palisade access to advanced bioinformatics tools and a curated dataset of over 1600 UC patient samples. This collaboration aims to identify predictive biomarkers using machine learning, ultimately improving treatment outcomes for patients with UC. Company executives expressed optimism about the potential benefits of this collaboration for ongoing therapeutic developments.
Read more →PALI▲ +42.5%on this news
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
Palisade Bio announced successful results from an ex-vivo study of PALI-2108, a prodrug for ulcerative colitis. The study demonstrated effective bioactivation in stool samples from both healthy individuals and UC patients, achieving a mean conversion rate of 90.1% within 24 hours. This supports PALI-2108's potential as a targeted therapy for moderate-to-severe UC.
Read more →PALI▲ +42.5%on this newsshared move
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
Palisade Bio announced successful results from an ex-vivo study of its product PALI-2108, showing effective bioactivation in stool samples from both healthy volunteers and patients with ulcerative colitis. The study demonstrated a mean conversion rate of 90.1%, indicating the potential of PALI-2108 as a targeted treatment for moderate-to-severe ulcerative colitis. This development provides a promising outlook for the company's therapeutic approach to inflammatory diseases.
Read more →PALI▲ +7.6%on this news· ran to +46% by day 3shared move
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
Palisade Bio, a biopharmaceutical company, has announced its participation in an upcoming Virtual Investor Lunch Break event scheduled for April 16, 2024. The event will feature presentations from CEO J.D. Finley and CMO Dr. Mitch Jones, who will provide an overview of the company's strategies and opportunities. A live webcast of the presentation will be accessible on the company’s website, and a replay will also be available afterward. This engagement underscores Palisade's commitment to investor relations and communication.
Read more →PALI▼ -24.9%on this newsshared move
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
Palisade Bio presented an overview of PALI-2108 at the IBD Innovate conference, highlighting its development for moderate-to-severe ulcerative colitis. The company is on track to initiate a Phase 1 clinical study by the end of the year, supported by a $500,000 funding agreement from the US Crohn's and Colitis Foundation. PALI-2108 is a locally acting PDE4 inhibitor prodrug aimed at treating ulcerative colitis.
Read more →PALI▼ -24.9%on this newsshared move
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis - PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing
Palisade Bio presented an overview of its product candidate PALI-2108 aimed at treating moderate-to-severe ulcerative colitis at the IBD Innovate conference. The presentation highlighted the differentiation of PALI-2108 and indicated a clear plan towards its clinical development. Additionally, PALI-2108 is set to progress to a Phase 1 clinical study later this year, with support from a significant funding agreement with the US Crohn's and Colitis Foundation.
Read more →PALIPalisade Bio Announces 1-for-15 Reverse Stock Split
Palisade Bio, Inc. announced a 1-for-15 reverse stock split effective April 5, 2024. This decision, approved by stockholders, aims to increase the company's share price and ensure compliance with Nasdaq's minimum price requirement. The split will not alter stockholders' percentage interests, although fractional shares will be compensated in cash.
Read more →PALIPalisade Bio Announces 1-for-15 Reverse Stock Split Carlsbad, CA
Palisade Bio, Inc. has announced a 1-for-15 reverse stock split of its common stock, effective April 5, 2024. This split aims to increase the per share trading price to meet Nasdaq's minimum listing requirements. The decision was approved by stockholders during a special meeting on March 25, 2024. The company will continue trading under the ticker "PALI" but with a new CUSIP number starting April 8, 2024.
Read more →PALI▲ +6%on this news
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
Palisade Bio reported its financial results for 2023 and provided an update on its lead candidate, PALI-2108, for treating ulcerative colitis. The company is on track to initiate a Phase 1 clinical study by the end of 2024 and has formed a Clinical Advisory Board. Financially, Palisade has sufficient cash to support operations through early 2025.
Read more →PALI▲ +6%on this newsshared move
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update - Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to c
Palisade Bio, Inc. reported its year-end 2023 financial results and provided a corporate update on its advancements. The company is on track to commence a Phase 1 study for its lead candidate, PALI-2108, aimed at treating moderate-to-severe ulcerative colitis by the end of 2024. They have formed a Clinical Advisory Board to guide their strategic initiatives and have secured sufficient funding to maintain operations through early 2025. Notably, positive preclinical data from PALI-2108 was presented at the 2024 Crohn's & Colitis Congress, indicating promising future developments.
Read more →PALIPalisade Bio to Present at Digestive Disease Week (DDW) 2024
Palisade Bio, Inc. has announced that its abstract has been accepted for a poster presentation at the Digestive Disease Week (DDW) 2024 conference in Washington, D.C. The event is scheduled for May 18-21, 2024, with Palisade Bio's poster titled 'LOCAL BIOACTIVATION AND EFFICACY OF PALI-2108' focusing on a PDE4 inhibitor prodrug for ulcerative colitis treatment. This underscores the company's efforts to develop innovative therapeutics for serious gastrointestinal diseases.
Read more →PALIPalisade Bio Provides Corporate Update and Reiterates Guidance
Palisade Bio has announced a corporate update, highlighting the advancement of its lead product, PALI-2108, towards a Phase 1 clinical study for ulcerative colitis. The company has streamlined its Board of Directors and appointed new members to align with its strategic goals. Additionally, it has presented positive preclinical data and secured funding through stock warrants.
Read more →PALIPalisade Bio Provides Corporate Update and Reiterates Guidance - Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision - Advancement of PALI-2108 f
Palisade Bio, Inc. provided a corporate update highlighting key advancements in its lead program, PALI-2108, aimed at treating moderate-to-severe ulcerative colitis (UC). The company is on schedule to initiate Phase 1 clinical studies by the end of 2024 and has presented encouraging preclinical data at a recent conference. Additionally, Palisade has restructured its Board of Directors to better align with the company's strategic vision, although this involved the resignation of several directors. The firm reports successful financial maneuvers, including the exercise of common stock warrants.
Read more →PALICorrection Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members
Palisade Bio, Inc. has issued a correction regarding the announcement of its Clinical Advisory Board appointments. The company clarified that the PALI-2108 Phase 1 clinical study is on track to commence in 2024, contrary to an earlier misstatement. This correction highlights the company's commitment to transparency and accurate communication.
Read more →PALIPalisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders
Palisade Bio has announced the formation of a Clinical Advisory Board, appointing Dr. Bruce Sands and Dr. Florian Rieder, two leading experts in gastroenterology. They will guide the advancement of Palisade’s product candidates including PALI-2108, aimed at treating ulcerative colitis. The company's commitment to a precision medicine approach is highlighted as they work towards launching a Phase 1 clinical study for PALI-2108 next year. Both experts emphasize the innovative nature and potential efficacy of the therapies being developed, particularly for conditions with unmet needs such as inflammatory bowel disease.
Read more →PALI▼ -35%on this news
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million Carlsbad, CA
Palisade Bio, Inc. announced the exercise of warrants that will generate approximately $2.5 million in gross proceeds. The existing warrants allow accredited investors to purchase over 3.4 million shares at a reduced price of $0.7313. Proceeds from this exercise are intended for general corporate purposes and working capital. The company plans to file a registration statement with the SEC regarding the resale of shares from the new replacement warrants. This financing move reflects ongoing confidence in Palisade's strategic initiatives in chronic gastrointestinal diseases.
Read more →PALI▲ +84.6%on this newsshared move
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
Palisade Bio announced positive preclinical results for PALI-2108, an orally delivered PDE4 inhibitor prodrug for ulcerative colitis. The data, presented at the Crohn's & Colitis Congress, indicates safety, localized bioactivation, and significant efficacy in mouse models. The company plans to advance PALI-2108 into Phase 1 clinical trials in 2024.
Read more →PALI▲ +84.6%on this newsshared move
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress - Preclinical data demonstrated PALI-2108 to be safe and well tolerated - PALI-2108 is orally delivered an
Palisade Bio, Inc. announced positive preclinical data for its lead program, PALI-2108, a phosphodiesterase-4B inhibitor, at the 2024 Crohn's & Colitis Congress. The data highlighted PALI-2108's safety profile, efficacy in animal models, and localized bioactivation, suggesting a promising approach for treating moderate-to-severe ulcerative colitis. The company intends to move forward with a Phase 1 clinical study later this year to further evaluate the therapy's potential. These developments signal a focused effort to address current limitations in ulcerative colitis treatments.
Read more →PALIPalisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
Palisade Bio, Inc. announced its abstract has been accepted for a poster presentation at the Crohn's & Colitis Congress scheduled for January 25-27, 2024, in Las Vegas. The presentation will focus on PALI-2108, a promising PDE4 inhibitor prodrug for treating ulcerative colitis. This event highlights the company's commitment to advancing therapies for serious gastrointestinal diseases.
Read more →PALIPalisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
Palisade Bio, Inc. announced that its abstract has been accepted for a poster presentation at the upcoming Crohn’s & Colitis Congress in Las Vegas. The presentation will focus on PALI-2108, a PDE4 inhibitor prodrug aimed at treating ulcerative colitis. The congress, scheduled for January 25-27, 2024, will allow Palisade to demonstrate its research and engage with the gastrointestinal disease community.
Read more →PALI▲ +9%on this news
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
Palisade Bio has received a second milestone payment from the US Crohn's and Colitis Foundation for its lead program, PALI-2108, aimed at treating moderate-to-severe ulcerative colitis. The funding will support the development of this orally administered PDE4B inhibitor prodrug, with an IND filing anticipated by Q3 2024. The company remains committed to advancing treatment options for inflammatory bowel disease.
Read more →PALI▲ +9%on this newsshared move
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
Palisade Bio has announced the receipt of a second milestone payment from the US Crohn's and Colitis Foundation, intended to support the development of its lead program, PALI-2108. This program aims to treat moderate-to-severe ulcerative colitis and is advancing toward IND-enabling studies, with an IND filing anticipated by the third quarter of 2024. The funding is part of a larger grant to support research initiatives, confirming the Foundation's investment in improving IBD treatments.
Read more →PALIPalisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook
Palisade Bio has reported its financial results for Q3 2023, highlighting a strong cash position of $15.3 million expected to support operations into 2025. The company is advancing its lead program, PALI-2108, an oral prodrug therapy for ulcerative colitis, with plans to begin a Phase 1 clinical study in 2024. Additionally, an exclusive licensing agreement with Giiant Pharma is set to expand its pipeline in the inflammatory bowel disease market, which is projected for significant growth. Overall, the company is confidently positioning itself for future development and market entry.
Read more →PALIPalisade Bio to Participate at the Virtual Investor Ask the CEO Conference
Palisade Bio (Nasdaq: PALI) has announced that its CEO, J.D. Finley, will participate in the Virtual Investor Ask the CEO Conference scheduled for October 25, 2023. This event aims to facilitate direct interaction between the company's management and the investment community, allowing investors to submit questions in advance or during the live event. The conference underscores Palisade Bio's commitment to transparency and investor engagement. A live webcast of the presentation will also be available on the company's website.
Read more →PALIPalisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
Palisade Bio has appointed Dr. Mitchell Jones as Chief Medical Officer, bringing extensive experience in gastrointestinal therapeutics. His leadership is expected to enhance the company's GI-focused pipeline, particularly in developing new treatment options for inflammatory bowel disease. The appointment includes an inducement grant of stock options and restricted stock units.
Read more →PALIPalisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules
Palisade Bio, Inc. has completed a registered direct offering of 2,339,398 shares, raising gross proceeds of approximately $2 million. The offering was facilitated by Ladenburg Thalmann & Co. Inc. and aims to bolster the company's working capital and general corporate needs. This capital injection will support their efforts in developing therapies for gastrointestinal issues, although the firm acknowledges existing risks related to market conditions and regulatory approvals.
Read more →PALIPalisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA
Palisade Bio has announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer, highlighting his extensive experience in developing therapeutics for gastrointestinal complications. Jones previously served in key leadership roles in various biotech companies and is recognized for his expertise in inflammatory bowel disease. The inducement grant to Jones includes stock options and restricted stock units, signifying the company's commitment to enhancing its leadership team. Palisade is optimistic about its new GI-focused pipeline and intends to improve treatment options for patients with IBD.
Read more →PALI▼ -45.8%on this newsshared move
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules Carlsbad, CA
Palisade Bio, Inc. announced a registered direct offering of common stock worth approximately $2 million, expected to close around September 11, 2023. The company plans to use the net proceeds primarily for working capital and corporate purposes. Institutional investors will purchase over 2.33 million shares at market price. The offering is made under a previously declared effective registration statement with the SEC, ensuring compliance and transparency.
Read more →PALI▲ +108.8%on this newsshared move
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease - Lead program, GT-2108 for the
Palisade Bio has entered into an exclusive licensing agreement with Giiant Pharma for the development of multiple oral drug candidates aimed at treating inflammatory bowel disease (IBD), including the lead program GT-2108 for moderate-to-severe ulcerative colitis. The agreement allows Palisade to develop, manufacture, and commercialize innovative therapies using Giiant's targeted prodrug platform, with an IND filing anticipated by Q3 2024. This partnership represents a significant transformation for Palisade's gastrointestinal-focused pipeline and emphasizes the unmet needs in IBD care. The initiative is buoyed by external support, including funding from the US Crohn's and Colitis Foundation.
Read more →PALIPalisade Bio Reports Second Quarter 2023 Financial Results
Palisade Bio, Inc. reported its financial results for the second quarter of 2023, highlighting a strong cash position with $16.4 million available to fund operations through 2024. The company is focused on advancing its gastrointestinal (GI) therapeutics pipeline and has made notable progress in corporate development activities. Despite an increase in net loss and research expenses, Palisade Bio is optimistic about its ongoing clinical trials and potential partnerships aimed at expanding its product offerings.
Read more →PALI▼ -62.7%on this newsshared move
Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
Palisade Bio announced that its U.S. Phase 2 PROFILE study of LB1148 for reducing post-surgical abdominal adhesions did not achieve its primary endpoint. The study showed no significant reduction in adhesions compared to placebo-treated patients following bowel resection surgery. Consequently, the company will not pursue further development for this indication and instead is focusing on expanding its pipeline in the gastrointestinal space. The management remains optimistic about identifying new opportunities despite these setbacks.
Read more →PALIPalisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
Palisade Bio, Inc. has announced the completion of patient enrollment in its dose optimization study for LB1148, a therapy aimed at addressing post-surgical abdominal adhesions. The CEO highlighted that achieving the enrollment target is a significant milestone for the clinical program. Topline data readout is anticipated in the coming weeks, which will inform further development of LB1148. The study aims to optimize dosing protocols while assessing pharmacokinetic and pharmacodynamic data to improve efficacy and safety.
Read more →PALIPalisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Palisade Bio, a biopharmaceutical company, has announced its participation in the Healthcare Virtual Conference hosted by Maxim Group LLC on June 22, 2023. CEO J.D. Finley will present, highlighting the company's focus on therapies for gastrointestinal complications. Notably, Palisade Bio is advancing its lead program, LB1148, which has shown promise in reducing post-surgical complications. The conference aims to showcase biotechnology and medical device innovations, providing a platform for critical industry discussions.
Read more →PALI▲ +9.1%on this news
Palisade Bio Promotes J.D. Finley to Chief Executive Officer
Palisade Bio has appointed J.D. Finley as Chief Executive Officer, effective immediately. Finley has been serving as interim CEO since October 2022, demonstrating leadership during a challenging transition period. The company has made notable progress in advancing its lead product, LB1148, which is in a Phase 2 study focusing on reducing digestive complications after surgery. Palisade Bio remains optimistic about the future of its therapeutic pipeline and potential contributions to patient care.
Read more →PALI▼ -7.6%on this news
Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
Palisade Bio is nearing topline data readout from its Phase 2 study for LB1148, which targets post-surgical abdominal adhesions and related GI complications. The company has also begun a dose optimization study, with 25% enrollment achieved. LB1148 has shown promise in previous studies for reducing surgical complications, and further data is expected to guide future trial design and development. The upcoming results could have significant implications for patient care in GI surgery.
Read more →PALIPalisade Bio Reports First Quarter 2023 Financial Results
Palisade Bio reported its financial results for the first quarter of 2023, indicating a net loss of $2.3 million, an improvement from $4.2 million in the same period last year. The company has enough cash, totaling $13.3 million, to sustain operations through 2024, bolstered by recent fundraising efforts. The CEO expressed optimism regarding the upcoming topline data from their Phase 2 adhesions study and the ongoing dose optimization study for LB1148. Additionally, a decrease in administrative expenses highlights the company's strategic cost-saving measures.
Read more →PALIPalisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
Palisade Bio has announced the enrollment and dosing of the first patient in its LB1148 dose optimization study. The study aims to explore whether a revised dosing protocol can improve the risk profile while maintaining efficacy across various indications. Approximately 32 healthy subjects will be enrolled to generate pharmacokinetic and pharmacodynamic data. The company is optimistic that the findings will inform its ongoing clinical development strategy for LB1148, which is designed to mitigate gastrointestinal complications.
Read more →PALIPalisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148
Palisade Bio, Inc. has received a Canadian patent for its lead development program, LB1148, aimed at treating autodigestion and protecting the intestinal barrier. This patent, which provides exclusive rights until 2035, supports the intellectual property for a broad-spectrum serine protease inhibitor. LB1148 has shown promising results in clinical studies for reducing post-surgical abdominal adhesions and is currently undergoing Phase 2 evaluation. Topline data from this study is anticipated in the upcoming second quarter of 2023.
Read more →PALI▲ +7.4%on this newsshared move
Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Palisade Bio, Inc. has announced a registered direct offering and concurrent private placement to raise $6 million by selling 2,272,723 shares of common stock at a price of $2.64 per share. The funds will support the company's working capital and general corporate purposes. The company, which focuses on therapies for gastrointestinal complications, plans to use the proceeds to further its research efforts and clinical programs.
Read more →PALI▲ +7.4%on this newsshared move
Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148
Palisade Bio announced that its partner, Newsoara Biopharma, has enrolled the first patient in a Phase 3 clinical trial for LB1148 in China. This milestone is critical as the trial aims to assess the efficacy of LB1148 in accelerating return of bowel function post-abdominal surgery. Palisade CEO J.D. Finley expressed confidence in LB1148's potential benefits for patients undergoing such procedures, supported by positive results from previous studies. The trial is fully funded by Newsoara, which is also responsible for making milestone payments to Palisade Bio.
Read more →PALI▼ -35.8%on this newsshared move
Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Palisade Bio, Inc. has announced a $6 million registered direct offering and concurrent private placement, allowing institutional investors to purchase shares at $2.64 each. The funds raised will be allocated to working capital and corporate purposes. The offering comprises registered common stock as well as unregistered shares and warrants. The transaction is anticipated to close around April 5, 2023, subject to standard closing conditions.
Read more →PALIPalisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update
Palisade Bio, Inc. reported its financial results for 2022 and outlined a corporate update, highlighting a strong balance sheet to fund operations through mid-2024. The company expects to release topline data from its Phase 2 study of LB1148 aimed at preventing post-surgical abdominal adhesions in Q2 2023. Despite positive developments, the company paused enrollment in the Phase 2 study and executed a cost-reduction plan leading to a 30% workforce reduction. The company aims to leverage its research advancements while navigating these challenges.
Read more →PALIPalisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent
Palisade Bio, Inc. announced that the European Patent Office (EPO) has issued an intention to grant for its LB1148 patent application, expected to be finalized in late 2023. This patent application includes claims for oral administration of serine protease inhibitors, which could have significant implications for treating postoperative complications. Additionally, LB1148 is under evaluation in a Phase 2 trial aimed at reducing intra-abdominal adhesions and improving bowel function recovery. The company is also committed to expanding its intellectual property portfolio to cover LB1148's global potential.
Read more →PALIPalisade Bio Promotes Robert McRae to Chief Operating Officer Mr. McRae is an industry veteran with a proven track record of operational, clinical, and strategic business development execution Carlsbad, CA
Palisade Bio has announced the promotion of Robert McRae to Chief Operating Officer, effective immediately. McRae, who joined the company in late 2021, brings a strong background in operational execution and strategic business development. The promotion reflects the company's confidence in his leadership amidst ongoing development efforts for their pipeline, particularly with the lead program LB1148, which targets gastrointestinal complications. Alongside this change, J.D. Finley, the interim CEO, has joined the Board of Directors to support these strategic initiatives.
Read more →PALIPalisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million
Palisade Bio, Inc. announced the early exercise of warrants resulting in $4.9 million in cash, enhancing its financial standing. This funding is expected to support the company's operations until the second half of 2024. A significant majority of the Series 1 and Series 2 warrants have been exercised, reflecting strong investor confidence. Palisade's lead program, LB1148, is showing promising results in ongoing clinical studies aimed at addressing gastrointestinal complications.
Read more →PALIPalisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event
Palisade Bio has announced that its Interim CEO, J.D. Finley, will present at the Virtual Investor 2023 Companies to Watch Event on January 17. The live presentation will highlight the company's focus on developing therapeutics for gastrointestinal complications, particularly their lead program LB1148. This program has shown promising results in clinical studies aimed at reducing surgical complications and accelerating gastrointestinal function recovery. A webcast of the presentation will be accessible on the company's website.
Read more →PALI▲ +6%on this news· ran to -26% by day 3shared move
Palisade Bio Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Palisade Bio, Inc. has successfully closed a registered direct offering and a concurrent private placement totaling $2.5 million. The company sold approximately 1,052,631 shares of common stock at a price of $2.375 each. The proceeds will be utilized for working capital and general corporate purposes. Additionally, Palisade is advancing its lead product, LB1148, which shows potential in treating gastrointestinal complications.
Read more →PALI▲ +61.5%on this newsshared move
Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules Carlsbad, CA
Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules CA - December 30, 2022 - Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastroi
Read more →PALIPalisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions Topline data readout from study expected in first half of 2023 Carlsbad, CA
Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions data readout from study expected in first half of 2023 CA - December 16, 2022 - Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies f
Read more →PALI▼ -6.8%on this news· ran to -26% by day 3
Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million
Proceeds extend cash runway to fund operations into early 2024 Carlsbad, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today annou
Read more →PALIPalisade Bio Regains Compliance with Nasdaq Listing Requirements
Carlsbad, CA, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that on December 1, 2022, it received notice from The Nasda
Read more →PALI▲ +81.9%on this news
Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery
Carlsbad, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for avoidance of acute and chronic post-surgical complications following gastrointestinal (GI) surgery, today announced that the U.S.
Read more →PALI▼ -7.9%on this news· ran to +49% by day 3shared move
Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer Established academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and m
Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and medical with LB1148 - serving as recent expert clinical advisor to Palisade Bio
Read more →PALI▼ -5.7%on this news· ran to +43% by day 3shared move
Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video
Video illustrates the potential of LB1148 to reduce the formation of adhesions in gastrointestinal (GI) tissues and accelerate the time to the return of normal GI function Carlsbad, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biophar
Read more →PALI▼ -18.6%on this news· ran to -40% by day 3shared move
Palisade Bio Announces Reverse Stock Split
Carlsbad, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced a 1-for-50 reverse split of its common stock, par value $0.
Read more →PALI▼ -18.6%on this news· ran to -40% by day 3shared move
Palisade Bio Announces Reverse Stock Split Carlsbad, CA
Bio Announces Reverse Stock Split CA - November 15, 2022 - Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced a 1-for-50 reverse split of its common stock,
Read more →PALIPalisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc., (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications (the “Company” or “Palisade”), reported its financial results for the quarte
Read more →PALI▼ -12.8%on this news
Palisade Bio Announces Executive Leadership Transition Board Appoints JD Finley to Interim Chief Executive Officer Carlsbad, CA
Bio Announces Executive Leadership Transition Appoints JD Finley to Interim Chief Executive Officer CA - October 11, 2022 - Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complicatio
Read more →PALI▼ -6.3%on this news
Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022
Carlsbad, CA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced its abstract was accepted for presentation at the American
Read more →PALI▼ -7.6%on this news
Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it had made equity grants to two new employees under
Read more →PALIPalisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference
CARLSBAD, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer of Pal
Read more →PALI▼ -9.1%on this news· ran to -24% by day 3
Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on Advancement of Lead Clinical Program, LB1148 Carlsbad, CA
Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on Advancement of Lead Clinical Program, LB1148 Carlsbad, CA - September 15, 2022 /GlobeNewswire/ - Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing ther
Read more →PALI▲ +18.3%on this newsshared move
Palisade Bio to Present at the Virtual Investor Innovations in Intestinal Health - Launching a Pivotal Phase 3 Study for Return of Postoperative Bowel Function Event
CARLSBAD, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer and Mi
Read more →PALI▼ -21.4%on this news
Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function
CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first patient has been dosed in its Phase 3 study e
Read more →PALI▼ -11%on this news· ran to -30% by day 1shared move
Forward-Looking Statements This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statem
Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complica
Read more →PALI▼ -11%on this news· ran to -30% by day 1shared move
Palisade Bio Announces Closing of $13.8 Million Upsized Underwritten Public Offering and Full Exercise of Over-Allotment Option
CARLSBAD, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the closing of its previously announced underwritten public o
Read more →PALIPalisade Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications (the “Company”), reported its financial results for the quarter ended June 30,
Read more →PALIPalisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering
CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the pricing of an underwritten public offering for gross proc
Read more →PALIPalisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health
CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the launch of its new corporate website, palisadebio.com and
Read more →PALIPalisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function
CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first patient has been screened in its Phase 3 stud
Read more →PALIPalisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function
Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant acceleration in the time to the return of normal GI function, and has the potential to prevent damage to GI tissues and shorten
Read more →PALIPalisade Bio to Present at the 2022 BIO International Convention
CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer of Palisade B
Read more →PALIPalisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 Ongoing Phase 2 study of LB1148 for the prevention of post-surgical abdominal adhesions CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PA
Read more →PALIPalisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires
CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021
Read more →PALIPalisade Bio Announces $2.0 Million Registered Direct Offering CARLSBAD, C.A.
Palisade Bio Announces $2.0 Million Registered Direct Offering CARLSBAD, C.A., May 6, 2022 Palisade Bio, Inc. (Nasdaq: PALI) (the Company or Palisade Bio ), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, toda
Read more →PALIPalisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery
NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study Newsoara to fully fund Phase 3 program in China Under the Co-Development Agreement, commencement of Phase 3
Read more →PALIRestoring Intestinal Barrier Health Corporate Presentation | May 2022 PALI (NASDAQ) | palisadebio.com Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-look
Restoring Intestinal Barrier Health Corporate Presentation | May 2022 PALI (NASDAQ) | palisadebio.com Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, wi
Read more →PALIPalisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements
CARLSBAD, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provided a business outlook and outlined its expected near-term pipeline
Read more →PALIPalisade Bio to Participate in the Virtual Investor Management and KOL Roundtable Event
CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that members of management will participate in the Virtual I
Read more →PALIPalisade Bio (Nasdaq: PALI) to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group and Hosted by M-Vest
CARLSBAD, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that of Palisade Bio, will participate in the 2022 Vir
Read more →PALIPalisade Bio (Nasdaq: PALI) Receives FDA “Study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery
CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced that the Company received a “Study May Proceed” letter from
Read more →PALIPalisade Bio (Nasdaq: PALI) Reports Year End 2021 Financial Results and Corporate Update
CARLSBAD, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies to aid patients suffering with acute and chronic gastrointestinal (GI) complications, today pr
Read more →PALIPalisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%
Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 16,
Read more →PALIRestoring Intestinal Barrier Health SAGES 2022 Presentation |
Restoring Intestinal Barrier Health SAGES 2022 Presentation | March 16, 2022 PALI (NASDAQ) | palisadebio.com Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements incl
Read more →PALIPalisade Bio (Nasdaq: PALI) to Present New Clinical Data of LB1148 for Preventing Adhesions in Conjunction with Next Big Thing Session at Society of American Gastrointestinal and Endoscopic Surgeons 2022 Annual Meeting
CARLSBAD, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was selected to present an ePoster entitled “Pooled-Analysis of Incide
Read more →PALIRestoring Intestinal Barrier Health Corporate Presentation | February 2022 PALI (NASDAQ) | palisadebio.com Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward
Restoring Intestinal Barrier Health Corporate Presentation | February 2022 PALI (NASDAQ) | palisadebio.com Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements includ
Read more →PALIPalisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference
CARLSBAD, Calif., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, will present at the Biocom Global Life Science Partnering Conference in
Read more →PALIPalisade Bio (NASDAQ: PALI) Adds Pharmaceutical Industry Executive Robert McRae to Leadership Team
CARLSBAD, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that Robert McRae has joined the senior management team
Read more →PALIPalisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting
CARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that data from a Pooled-Analysis of Studies LBS-IST-POI
Read more →PALIRestoring Intestinal Barrier Health Corporate Presentation | January 2022 PALI (NASDAQ) | palisadebio.com Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-
Restoring Intestinal Barrier Health Corporate Presentation | January 2022 PALI (NASDAQ) | palisadebio.com Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include
Read more →PALIPalisade Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase
CARLSBAD, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces that they will present at the H.C. Wainwright BIOCONNECT Virt
Read more →PALIPalisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus
Issuance of Additional U.S. Patent No11,202,768 Further Bolsters Palisade Bio’s Patent Portfolio The Company Continues to Advance LB1148 for Key Indications After LB1148 Topline Efficacy Results from Phase 2 Trial Demonstrated Accelerated Return of Bowel Function Following Gastr
Read more →PALIPalisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035
CARLSBAD, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the company will be granted a patent from the European
Read more →PALIPalisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires, Including Nick McCoy, Vice President of Clinical Operations
CARLSBAD, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a clinical stage biopharmaceutical company advancing oral therapies that help patients with acute and chronic gastrointestinal (GI) complications (the “Company”), today announced that it had ma
Read more →PALIPalisade Bio Reports Third Quarter Financial Results
CARLSBAD, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies that help patients with acute and chronic gastrointestinal (GI) complications, today provides a
Read more →PALIRestoring Intestinal Barrier Health Corporate Presentation | October 2021 PALI (NASDAQ) | palisadebio.com Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-
| October 2021 PALI (NASDAQ) | palisadebio.com Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research an
Read more →PALIPalisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the treatment of Central Nervous System Disorders Carlsbad, CA. (GLOBE NEWSWIRE)
Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the treatment of Central Nervous System Disorders Carlsbad, CA. (GLOBE NEWSWIRE)--Oct 22, 2021 Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharma company advancing oral therapies that help patients with acute
Read more →PALIRestoring Intestinal Barrier Health Corporate Presentation | September 2021 PALI (NASDAQ) | palisadebio.com
Restoring Intestinal Barrier Health Corporate Presentation | September 2021 PALI (NASDAQ) | palisadebio.com 2 Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward - looking statements. Such forward - looking statements
Read more →PALIPalisade Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
CARLSBAD, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces today that Chief Executive Officer Tom Hallam, Ph.D. will present at the
Read more →PALIPalisade Bio Reports Second Quarter Financial Results and Provides Business Update
CARLSBAD, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provides a business update and releases its fin
Read more →PALIPalisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center
$5.2M invested at $3.45 stock price Funds to be used to advance clinical development of LB1148 Investment driven by Phase 2 clinical data that the medical center believes may lead to LB1148 being used as standard of care for the protection and healing of the GI tract in surgica
Read more →PALIPalisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery
Statistically significant 1.1-day acceleration in return of bowel function Favorable overall safety profile in 120 patients CARLSBAD, Calif. and SHANGHAI, China, July 29, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) and co-development partner Newsoara today announ
Read more →PALIPalisade Bio Enters into Worldwide In-Licensing Agreement with University of California for Technology to Support Target Identification, Drug Discovery, and Clinical Development
CARLSBAD, Calif., July 13, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it entered into an exclusive license with the Regents of the Un
Read more →PALIPalisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function and Reduction of Post-Surgical Adhesions
CARLSBAD, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the launch of its Clinical Steering Committee (CSC) designed to prov
Read more →PALIRestoring Intestinal Barrier Health Corporate Presentation | May 2021 PALI (NASDAQ) | palisadebio.com
Restoring Intestinal Barrier Health Corporate Presentation | May 2021 PALI (NASDAQ) | palisadebio.com 2 Forward Looking Statements This communication contains "forward - looking" statements, including, without limitation, statements related to the anticipated benefits of the tra
Read more →PALIPalisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery
LB1148 was previously granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of postoperative GI dysfunction associated with pediatric cardiovascular surgery A Phase 2 gastrointestinal surgery trial that will evaluate LB1148 for reducti
Read more →PALIPalisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China
CARLSBAD, Calif. and SHANGHAI, China, May 07, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), and co-development partner Newsoara today announce completion of a Phase 2 clinical trial evaluating lead drug candidate LB1148 for accelerating return of bowel function asso
Read more →PALIPalisade Bio Hosting Key Opinion Leader Webinar on LB1148, an Oral Serine Protease Inhibitor for Postoperative GI Dysfunction
CARLSBAD, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it will host a key opinion leader (KOL) webinar event on LB1148
Read more →PALIRestoring Intestinal Barrier Health Corporate Presentation | April 2021 PALI (NASDAQ) | palisadebio.com
Restoring Intestinal Barrier Health Corporate Presentation | April 2021 PALI (NASDAQ) | palisadebio.com 2 Forward Looking Statements This communication contains "forward - looking" statements, including, without limitation, statements related to the anticipated benefits of the t
Read more →PALINSI - 566 STEM CELL PROGRAMS: PARTNERING BRIEF
NSI - 566 STEM CELL PROGRAMS: PARTNERING BRIEF SUMMARY OF OPPORTUNITY : PROGRAMS AND INDICATIONS NSI - 566 is an allogeneic neural stem cell line that is currently being evaluated in China in a placebo - controlled Phase II clinical trial for chronic ischemic stroke, and has bee
Read more →PALISeneca Biopharma (NASDAQ: SNCA) Partnering Opportunities for CNS Diseases
1 Seneca Biopharma (NASDAQ: SNCA) Partnering Opportunities for CNS Diseases 2 Assets: first - in - class stem cell - based treatments for neurological diseases Clinical Stage: ALS and Chronic Stroke (Phase II), Spinal Cord Injury (Phase I) Seeking Partnership & Business Developm
Read more →PALISeneca Biopharma (NASDAQ: SNCA) NASDAQ listed company dedicated to developing reduced - risk innovative biopharmaceuticals for the treatment of human immunological diseases
1 Seneca Biopharma (NASDAQ: SNCA) NASDAQ listed company dedicated to developing reduced - risk innovative biopharmaceuticals for the treatment of human immunological diseases 2 DISCLAIMER The following slides and information contained therein are based upon Seneca Biopharma succ
Read more →PALIneuralstem.com Corporate Overview March, 2018 1
neuralstem.com Corporate Overview March, 2018 1 neuralstem.com Safe Harbor Statement 2 Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in Section 27 A of the Securities Act of
Read more →PALIneuralstem.com Treatment of ALS with Neural Stem Cells Cell & Gene Therapy World 1 Karl Johe, Ph.D., CSO & Founder Neuralstem, Inc.
neuralstem.com Treatment of ALS with Neural Stem Cells Cell & Gene Therapy World 1 Karl Johe, Ph.D., CSO & Founder Neuralstem, Inc. January 24, 2018 neuralstem.com Safe Harbor Statement 2 Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This pr
Read more →PALIneuralstem.com Neuroscience Innovation Forum January 7, 2018 1
neuralstem.com Neuroscience Innovation Forum January 7, 2018 1 neuralstem.com Safe Harbor Statement neuralstem.com 2 Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in Section
Read more →PALISafe Harbor Statement Although we believe that we have a reasonable basis for each forward - looking statement contained in this presentation, we caution you that forward - looking
Safe Harbor Statement Although we believe that we have a reasonable basis for each forward - looking statement contained in this presentation, we caution you that forward - looking statements are not guarantees of future performance and that our actual results of operations, fina
Read more →PALIFebruary 2017 Corporate & Clinical Overview
February 2017 Corporate & Clinical Overview Safe Harbor Statement Although we believe that we have a reasonable basis for each forward - looking statement contained in this presentation, we caution you that forward - looking statements are not guarantees of future performance an
Read more →PALINeuralstem Announces Plan of Reorganization to Further Align Business with Strategic Intent GERMANTOWN, Md.
Neuralstem Announces Plan of Reorganization to Further Align Business with Strategic Intent GERMANTOWN, Md., May 20, 2016 -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell
Read more →PALINeuralstem to Raise $1.08 Million
Neuralstem to Raise $1.08 Million GERMANTOWN, MD, May 12, 2016 - Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that it has entered into a defi
Read more →PALINeuralstem Reports Fiscal First Quarter 2016 Results and Business Update GERMANTOWN, MD
Neuralstem Reports Fiscal First Quarter 2016 Results and Business Update GERMANTOWN, MD, May 9, 2016 -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, reporte
Read more →PALINeuralstem Announces Proposed Public Offering of Securities GERMANTOWN, MD
Neuralstem Announces Proposed Public Offering of Securities GERMANTOWN, MD, May 2, 2016 -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that
Read more →PALINeuralstem Receives NASDAQ Notice of Bid Price Deficiency GERMANTOWN, MD
Neuralstem Receives NASDAQ Notice of Bid Price Deficiency GERMANTOWN, MD, April 21, 2016 -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that on A
Read more →PALIApril 2016 Corporate Presentation NEURALSTEM, INC. Safe Harbor Statement Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defi
April 2016 Corporate Presentation NEURALSTEM, INC. Safe Harbor Statement Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in Section 27 A of the Securities Act of 1933 as amende
Read more →PALIMarch 15, 2016 28 th Annual Roth Conference
March 15, 2016 28 th Annual Roth Conference March 2016 28 th Annual Roth Conference NEURALSTEM, INC. Safe Harbor Statement Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in S
Read more →PALINeuralstem Reports Fourth Quarter and Year End 2015 Fiscal Results and Business Update FDA Approval to Commence Phase 2 Major Depressive Disorder Clinical Trial Strengthening of Executive Leadership GERMANTOWN, MD
Neuralstem Reports Fourth Quarter and Year End 2015 Fiscal Results and Business Update FDA Approval to Commence Phase 2 Major Depressive Disorder Clinical Trial Strengthening of Executive GERMANTOWN, MD, March 14, 2016 -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical
Read more →PALIMarch 2016 Corporate Presentation NEURALSTEM, INC. Safe Harbor Statement Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defi
March 2016 Corporate Presentation NEURALSTEM, INC. Safe Harbor Statement Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in Section 27 A of the Securities Act of 1933 as amende
Read more →PALINeuralstem Appoints Richard Daly as President and Chief Executive Officer GERMANTOWN, MD
Neuralstem Appoints Richard Daly as President and Chief Executive Officer GERMANTOWN, MD, February 16, 2016 - Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology,
Read more →PALINEURALSTEM PRESENTED CELL THERAPY UPDATE
NEURALSTEM PRESENTED CELL THERAPY UPDATE AT PHACILITATE CELL & GENE THERAPY WORLD CONFERENCE NSI-566 Trial Data Reveals Biological Activity Across Multiple Neurodegenerative Diseases: ALS, Chronic Spinal Cord Injury, and Stroke MD, January 27, 2016 -- Neuralstem, Inc. (Nasdaq
Read more →PALINEURALSTEM'S PRECLINICAL ALZHEIMER'S
NEURALSTEM'S PRECLINICAL ALZHEIMER'S DISEASE DATA PUBLISHED IN STEM CELLS TRANSLATIONAL MEDICINE MD, January 11, 2016 -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for cent
Read more →PALIData for Neuralstem's Novel NSI-189 Molecule in Major Depressive Disorder Published in Molecular Psychiatry Phase 1b Data Demonstrate Potential of Oral Neurogenesis-based Therapies GERMANTOWN, Md.
Data for Neuralstem's Novel NSI-189 Molecule in Major Depressive Disorder Published in Molecular Psychiatry Phase 1b Data Demonstrate Potential of Oral Neurogenesis-based GERMANTOWN, Md., December 8, 2015 - Neuralstem, Inc. (NASDAQ: CUR) today announced the publication of Pha
Read more →PALINeuralstem Reports Third Quarter 2015 Financial Results Adds Depth to Management Team with Appointment of Industry Veterans as Second Asset Advances towards Phase 2 GERMANTOWN, MD
Neuralstem Reports Third Quarter 2015 Depth to Management Team with Appointment of Industry Veterans as Second Asset Advances towards Phase 2 GERMANTOWN, MD, November 9, 2015 -- Neuralstem, Inc. (Nasdaq: CUR) a biopharmaceutical company leveraging its unique human neural stem
Read more →PALIInvestigator Provides Phase II Update on ALS Cell Therapy at American Neurological Association Annual Meeting
Investigator Provides Phase II Update on ALS Cell Therapy at American Neurological Association Annual Meeting Md., Sept. 29, 2015 - Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatment
Read more →PALINeuralstem Reports Second Quarter 2015 Financial Results GERMANTOWN, MD
Neuralstem Reports Second Quarter 2015 GERMANTOWN, MD, August 10, 2015 -- Neuralstem, Inc. (Nasdaq: CUR) a biopharmaceutical company developing neural stem cell-derived small molecule and cell therapy treatments for central nervous system diseases, reported its financial resul
Read more →PALIUS DISTRICT COURT RULES IN FAVOR OF NEURALSTEM
US DISTRICT COURT RULES IN FAVOR OF NEURALSTEM IN PATENT INFRINGEMENT CASE GERMANTOWN, MD, July 23, 2015 -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous
Read more →PALINeuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market GERMANTOWN, MD
Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market GERMANTOWN, MD, June 29, 2015 -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nerv
Read more →PALIPRECLINICAL DATA ON NEURALSTEM'S GENETICALLY MODIFIED HK532-IGF-1 STEM CELLS IN ALZHEIMER'S
PRECLINICAL DATA ON NEURALSTEM'S GENETICALLY MODIFIED HK532-IGF-1 STEM CELLS IN ALZHEIMER'S DISEASE PRESENTED AT INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH GERMANTOWN, MD, June 26, 2015 -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell t
Read more →PALINeuralstem Reports First Quarter 2015 Financial Results And Provides Business and Clinical Update GERMANTOWN, MD
Neuralstem Reports First Quarter 2015 And Provides Business GERMANTOWN, MD, May 8, 2015 -- Neuralstem, Inc. (NYSE MKT: CUR) a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases,
Read more →PALINEURALSTEM
NEURALSTEM APPOINTS JONATHAN LLOYD JONES AS CHIEF FINANCIAL OFFICER MD, May 6, 2015 -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, an
Read more →PALINEURALSTEM REPORTS FISCAL 2014 FOURTH QUARTER FINANCIAL AND YEAR-END
NEURALSTEM REPORTS FISCAL 2014 FOURTH QUARTER FINANCIAL AND YEAR-END BUSINESS RESULTS GERMANTOWN, MD, March 16, 2015 -- Neuralstem, Inc. (NYSE MKT: CUR) (the "Company" or "Neuralstem") today reported its financial results for the fourth quarter and year ended December 31, 201
Read more →PALIBarclay's Global Healthcare Conference
Barclay's Global Healthcare Conference March 12, 2015 Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in Section 27 A of the Securities Act of 1933 as amended, and section 21 E
Read more →PALIThe 17 th Annual BIO CEO & Investor Conference
The 17 th Annual BIO CEO & Investor Conference February 9, 2015 Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in Section 27 A of the Securities Act of 1933 as amended, and se
Read more →PALINEURALSTEM NSI-189 PHASE IB MAJOR DEPRESSION DISORDER NEUROGENIC BIOMARKER DATA PRESENTED AT THE CNS SUMMIT Depression Biomarker Analysis Shows NSI-189 is Rapidly and Persistently Efficacious GERMANTOWN, MD
NEURALSTEM NSI-189 PHASE IB MAJOR DEPRESSION BIOMARKER DATA PRESENTED AT THE CNS SUMMIT Depression Biomarker Analysis Shows NSI-189 is Rapidly and Persistently Efficacious GERMANTOWN, MD, November 17, 2014 -- Neuralstem, Inc. (NYSE MKT: CUR) announced that blood-based biomar
Read more →PALINEURALSTEM ANNOUNCES PUBLICATION OF LONG TERM CELL SURVIVAL FROM PHASE I NSI-566 ALS STUDY IN THE JOURNAL "ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY" Study Concludes NSI-566 Cells Survived for up to 2.5 Years After
NEURALSTEM ANNOUNCES PUBLICATION OF LONG TERM CELL SURVIVAL FROM PHASE I NSI-566 ALS STUDY IN THE JOURNAL "ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY" Study Concludes NSI-566 Cells Survived for up to 2.5 Years After Transplantation
Read more →PALIPlanet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM ALZHEIMER'S
Contact: Planet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM ALZHEIMER'S DISEASE ANIMAL DATA PRESENTED AT THE CONGRESS OF NEUROLOGICAL SURGEONS ANNUAL MEETING GER
Read more →PALIPlanet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 FIRST PATIENT TREATED IN NEURALSTEM PHASE I SPINAL CORD IN
Contact: Planet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 FIRST PATIENT TREATED IN NEURALSTEM PHASE I SPINAL CORD INJURY STEM CELL TRIAL THROUGH THE UC SAN DIEGO SANFORD S
Read more →PALIPlanet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM ALS INVESTIGATOR PRESENTS LONG-TERM FOLLOW UP P
Contact: Planet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM ALS INVESTIGATOR PRESENTS LONG-TERM FOLLOW UP PHASE I DATA Some Patients Continue to Show Slowed Dise
Read more →PALINeural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals September 2014 NYSE MKT: CUR Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward -
Neural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals September 2014 NYSE MKT: CUR Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in Section 27 A of the Securi
Read more →PALIPlanet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758
Contact: Planet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM REPORTS SECOND QUARTER FINANCIAL AND PROVIDES BUSINESS AND CLINICAL UPDATE GERMANTOWN, MD, August 8,
Read more →PALIPlanet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM FINAL PHASE I
Contact: Planet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM FINAL PHASE I DEPRESSION DATA PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY ANNUAL
Read more →PALIPlanet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM APPOINTS SANDFORD DREXEL SMITH, FORMER GENZYME
Contact: Planet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM APPOINTS SANDFORD DREXEL SMITH, FORMER GENZYME EXECUTIVE VICE PRESIDENT, TO BOARD OF DIRECTORS MD, Ma
Read more →PALIPlanet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM SPINAL CORD INJURY STEM CELL TRIAL APPROVED TO
Planet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM SPINAL CORD INJURY STEM CELL COMMENCE AT UNIVERSITY OF CALIFORNIA, SAN DIEGO NSI-566 to be Tested in Patients w
Read more →PALIPlanet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 STUDY SHOWS NEURALSTEM CELLS TRANSPLANTED IN
Contact: Planet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 STUDY SHOWS NEURALSTEM CELLS TRANSPLANTED SIGNIFICANTLY IMPROVE POST-STROKE SYMPTOMS IN RATS First Study To Vali
Read more →PALIPlanet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 FINAL RESULTS OF NEURALSTEM PHASE I
Contact: Planet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 FINAL RESULTS OF NEURALSTEM PHASE I STEM CELL TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS PUBLISHED IN ANNALS OF NEURO
Read more →PALIPlanet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM ANNOUNCES 2013
Contact: Planet Communications - Media Relations: Deanne Eagle 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM ANNOUNCES 2013 FINANCIAL RESULTS ROCKVILLE, MD, March 10, 2014 - Neuralstem, Inc. (NYSE MKT: CUR) tod
Read more →PALISLIDE PRESENTATION
SLIDE PRESENTATION
Read more →PALIDeanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 747.222.7012
Deanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 747.222.7012 FIRST PATIENT TREATED IN NEURALSTEM CHINA STEM CELL TRIAL TO TREAT STROKE MOTOR DEFICITS ROCKVILLE, MD, January 13, 2014 -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patien
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM CLOSES $ 20
Deanne Eagle - Media Relations 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 CLOSES $20 MILLION REGISTERED DIRECT OFFERING ROCKVILLE, MD, January 9, 2014 -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that on January 8
Read more →PALINEURALSTEM TO RAISE $19.65
Deanne Eagle - Media Relations 917.837.5866 MDC Group - Investor Relations: Susan Roush 747.222.7012 David Castaneda 414.351.9758 NEURALSTEM TO RAISE $19.65 MILLION IN REGISTERED DIRECT OFFERING ROCKVILLE, Maryland, January 3, 2014 - Neuralstem, Inc. (NYSE MKT: CUR) announce
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM REPORTS THIRD QUARTER FINANCIAL AND PROVIDES BUSINESS AND CLINICAL UPDATE ROCKVILLE, Md., November 12, 2013 -- Neuralstem, Inc. (NYSE MKT: CUR) today reported financial result
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 747.222.7012 UNIVERSITY OF MICHIGAN HEALTH SYSTEM TREATS ITS FIRST PATIENTS IN NEURALSTEM'S PHASE II ALS STEM CELL TRIAL
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 747.222.7012 UNIVERSITY OF MICHIGAN HEALTH SYSTEM TREATS ITS FIRST PATIENTS IN NEURALSTEM'S PHASE II ALS STEM CELL TRIAL First of Five Cohorts Completed in Dose ROCKVILLE, MD, October 9, 2013 -- Neu
Read more →PALISLIDE PRESENTATION World Leader in Neural Stem Cell Science Corporate Overview September 2013 Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looki
World Leader in Neural Stem Cell Science Corporate Overview September 2013 Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in Section 27 A of the Securities Act of 1933 as amen
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM TO RAISE $4
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM TO RAISE $4 MILLION IN REGISTERED ROCKVILLE, Maryland, September 5, 2013 - Neuralstem, Inc. (NYSE MKT: CUR) announced today that it has entered into agreements with certain ac
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM CELLS REVERSE COGNITIVE DEFECT IN BRAIN-IRRADIATED RATS
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM CELLS REVERSE COGNITIVE DEFECT RATS, UNIVERSITY OF CALIFORNIA IRVINE PAPER SHOWS ROCKVILLE, Md., August 1, 2013 -- Neuralstem, Inc. (NYSE MKT: CUR) announced that a paper publ
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM'S CELLS INDUCE IMPROVEMENT IN ACUTE SPINAL CORD INJURY RATS
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM'S CELLS INDUCE IMPROVEMENT IN ACUTE SPINAL CORD INJURY RATS, UCSD STUDY SHOWS Md, May 28, 2013 -- Neuralstem, Inc. (NYSE MKT: CUR) announced that a paper published today in the
Read more →PALIWorld Leader in Neural Stem Cell Science Corporate Overview May 2013 Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined
World Leader in Neural Stem Cell Science Corporate Overview May 2013 Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in Section 27 A of the Securities Act of 1933 as amended, a
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM ALS TRIAL INVESTIGATOR AND PATIENT ON SIRIUS XM Dr. Eva Feldman and Ted Harada to discuss Neuralstem ALS Trial
Contact: Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM ALS TRIAL INVESTIGATOR AND PATIENT ON SIRIUS XM Dr. Eva Feldman and Ted Harada to discuss Neuralstem ALS Trial ROCKVILLE, Md., May 8, 2013 -- Neuralstem, Inc. (NYS
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM AND THE NATIONAL FOOTBALL LEAGUE ALUMNI ASSOCIATION ANNOUNCE INITIATIVE ON BRAIN INJURY TREATMEN
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 THE NATIONAL FOOTBALL LEAGUE ALUMNI ASSOCIATION ANNOUNCE INITIATIVE ON BRAIN INJURY TREATMENT Investigating feasibility of NSI-189 trial to treat cognitive and psychiatric impairment from
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM RECEIVES FDA APPROVAL TO COMMENCE PHASE II STEM CELL TRIAL IN AMYTROPHIC LATERAL SCLEROSIS Trial Expands to Tw
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM RECEIVES FDA APPROVAL TO COMMENCE PHASE II STEM CELL TRIAL IN AMYTROPHIC LATERAL SCLEROSIS Trial Expands to Two Centers; Approval Includes Significant Increase in Dosing ROCK
Read more →PALINEURALSTEM SECURES $8 MILLION IN DEBT
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM SECURES $8 MILLION IN DEBT FINANCING FROM HERCULES ROCKVILLE, MD, March 25, 2013 - Neuralstem, Inc. (NYSE MKT: CUR) announced today that it secured $8 million in debt financin
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM ANNOUNCES 2012 FINANCIAL RESULTS
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM ANNOUNCES 2012 FINANCIAL RESULTS, PROVIDES CLINICAL TRIALS UPDATE ROCKVILLE, MD, March 15, 2013 -- Neuralstem, Inc. (NYSE MKT: CUR) today provided an update on its clinical tr
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM GRANTS LICENSES FOR CENTRAL NERVOUS SYSTEM THERAPY SURGICAL DEVICES TO CEDARS-SINAI
Contact: Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM GRANTS LICENSES FOR CENTRAL THERAPY SURGICAL DEVICES TO CEDARS-SINAI MEDICAL CENTER ROCKVILLE, MD, February 20, 2013 -- Neuralstem, Inc. (NYSE MKT: CUR) announced th
Read more →PALIWorld Leader in Neural Stem Cell Science Corporate Overview February 2013 Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as def
World Leader in Neural Stem Cell Science Corporate Overview February 2013 Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in Section 27 A of the Securities Act of 1933 as amend
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM RECEIVES FDA APPROVAL TO COMMENCE SPINAL CORD INJURY TRIAL NSI-566 to be tested in patients with chronic spina
Contact: Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM RECEIVES FDA APPROVAL TO COMMENCE SPINAL CORD INJURY TRIAL NSI-566 to be tested in patients with chronic spinal cord injury Maryland, January 14, 2013 - Neuralstem,
Read more →PALINeural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals January 2013 NYSE MKT: CUR Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - lo
Neural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals January 2013 NYSE MKT: CUR Safe Harbor statements under the Private Securities Litigation Reform Act of 1995 : This presentation contains forward - looking statements as defined in Section 27 A of the Securiti
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL PROGRAMS AND BUSINESS HIGHLIGHTS ROCKV
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL PROGRAMS AND BUSINESS HIGHLIGHTS Maryland, November9, 2012-Neuralstem, Inc. (NYSE MKT: CUR) reported its
Read more →PALIEXHBIT 99.01 Contact: Deanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 818.222.8330 FDA APPROVES NEURALSTEM TO TREAT SECOND COHORT IN NSI-189 PHASE IB TRIAL IN MAJOR DEPRESSIVE DISORDER First Ib
Deanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 818.222.8330 FDA APPROVES NEURALSTEM TO TREAT SECOND COHORT IN NSI-189 PHASE IB TRIAL IN MAJOR DEPRESSIVE DISORDER First Ib Patient Treated in Escalated Dosing of Neurogenic Small Molecule Drug ROCKVI
Read more →PALIDeanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 818.222.8330
Deanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 818.222.8330 NEURALSTEM APPROVED TO COMMENCE ISCHEMIC STROKE TRIAL IN CHINA ROCKVILLE, Maryland, September 27, 2012 - Neuralstem, Inc. (NYSE MKT: CUR) announced it has been approved to commence a clini
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM to Raise $7.0 Million in Registered Direct Offering
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 to Raise $7.0 Million in Registered Direct Offering ROCKVILLE, Maryland, September 13, 2012 - Neuralstem, Inc. (NYSE MKT: CUR) today announced the pricing of a registered direct offering
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM GRANTS FIRST LICENSES FOR CNS THERAPY SURGICAL DEVICES Industry-breakthrough Spinal Platform and Floating Cann
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM GRANTS FIRST LICENSES FOR CNS THERAPY SURGICAL DEVICES Industry-breakthrough Spinal Platform and Floating Cannula Used in ALS Stem Cell Trial ROCKVILLE, MD, September 6, 2012
Read more →PALIDATED AUGUST 14, 2012 Contact: Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF 6,000,000
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF 6,000,000 SHARES OF COMMON STOCK ROCKVILLE, Maryland, August 14, 2012 - Neuralstem, Inc. (NYSE MKT: CUR) today announced the pricing of
Read more →PALINeural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals August 2012 NYSE MKT: CUR Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This presentation contains forward - look
Neural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals August 2012 NYSE MKT: CUR Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This presentation contains forward - looking statements as defined in Section 27A of the Securities
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 FIRST PATIENTS DOSED IN i b PHASE OF NEURALSTEM'S NSI-189
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 PATIENTS DOSED IN ib PHASE OF NEURALSTEM'S NSI-189 TRIAL IN MAJOR DEPRESSIVE DISORDER ROCKVILLE, Maryland, June 25, 2012- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patien
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM ANNOUNCES 2011 FINANCIAL RESULTS
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM ANNOUNCES 2011 FINANCIAL RESULTS, PROVIDES OPERATIONS UPDATE Maryland, March 29, 2012 - Neuralstem, Inc. (NYSE Amex: CUR) today provided a financial and operations update for
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 FOURTEENTh PATIENT DOSED IN Neuralstem ALS Stem Cell
Contact: Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 PATIENT DOSED IN Neuralstem ALS Stem Cell TRIAL ROCKVILLE, Maryland, March 7, 2012- Neuralstem, Inc. (NYSE Amex: CUR) announced that the second patient to receive stem cells in
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM TO RAISE $5.2
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM TO RAISE $5.2 MILLION IN REGISTERED ROCKVILLE, Maryland, February 6, 2012 - Neuralstem, Inc. (NYSE Amex: CUR) announced today that it has entered into agreements with certain
Read more →PALINeural Stem Cell Technology Platform for Cell Therapeutics and Pharmaceuticals NYSE Amex: CUR www.neuralstem.com 2 NEURALSTEM, INC. SAFE HARBOR STATEMENT This presentation contains forward - looking statements. Neuralste
Neural Stem Cell Technology Platform for Cell Therapeutics and Pharmaceuticals NYSE Amex: CUR www.neuralstem.com 2 NEURALSTEM, INC. SAFE HARBOR STATEMENT This presentation contains forward - looking statements. Neuralstem wishes to caution the readers of and listeners participat
Read more →PALIDeanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM'S NSI-189 TRIAL IN MAJOR DEPRESSIVE DISORDER RECEIVES FDA APPROVAL TO ADVANCE TO PHASE IB First Neuroregenerat
Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM'S NSI-189 TRIAL IN MAJOR DEPRESSIVE DISORDER RECEIVES FDA APPROVAL TO ADVANCE TO PHASE IB First Neuroregenerative Compound Tested In Depression ROCKVILLE, Maryland, December,
Read more →PALIDeanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 818.222.8330 DR. EVA FELDMAN, PRINCIPAL INVESTIGATOR
Deanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 818.222.8330 DR. EVA FELDMAN, PRINCIPAL INVESTIGATOR, PRESENTS INTERIM DATA ON NEURALSTEM ALS TRIAL ROCKVILLE, Maryland, September 27, 2011 - Neuralstem, Inc. (NYSE Amex: CUR) announced that Eva Feldman
Read more →PALINeural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals NYSE Amex: CUR 2 NEURALSTEM, INC. SAFE HARBOR STATEMENT This presentation contains forward - looking statements. Neuralstem wishes to caution the read
Neural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals NYSE Amex: CUR 2 NEURALSTEM, INC. SAFE HARBOR STATEMENT This presentation contains forward - looking statements. Neuralstem wishes to caution the readers of and listeners participating in this presentation tha
Read more →PALINeuralstem Awarded Department of Defense Contract for Brain Cancer Research ROCKVILLE, Md.
Neuralstem Awarded Department of Defense Contract for Brain Cancer Research ROCKVILLE, Md., Aug. 3, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced it received a U.S. Department of Defense (DOD) contract to develop its human neural stem cell technology for the t
Read more →PALIMeg McElroy, Shareholder Relations 301.366.4960 Deanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 818.222.8330 NEURALSTEM UPDATES NSI-189 MAJOR DEPRESSION TRIAL ADVANCING TO FINAL PHASE
Meg McElroy, Shareholder Relations 301.366.4960 Deanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 818.222.8330 NEURALSTEM UPDATES NSI-189 MAJOR DEPRESSION TRIAL ADVANCING TO FINAL PHASE Ia COHORT ROCKVILLE, Maryland, June 20, 2011 - Neuralstem, Inc. (N
Read more →PALIMeg McElroy, Shareholder Relations 301.366.4960 Deanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 818.222.8330
Meg McElroy, Shareholder Relations 301.366.4960 Deanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 818.222.8330 NEURALSTEM UPDATES ALS CLINICAL TRIAL PROGRESS APPROVED BY SAFETY MONITORING BOARD TO MOVE TO CERVICAL TRANSPLANTATIONS ROCKVILLE, Maryland,
Read more →PALIMeg McElroy, Shareholder Relations 301.366.4960 Deanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 818.222.8330 NEURALSTEM AND SUMMIT PHARMACEUTICALS ENTER INTO EXCLUSIVE AGENCY AGREEMENT
Meg McElroy, Shareholder Relations 301.366.4960 Deanne Eagle, Media Relations 917.837.5866 Susan Roush, Investor Relations 818.222.8330 NEURALSTEM AND SUMMIT PHARMACEUTICALS ENTER INTO EXCLUSIVE AGENCY AGREEMENT TO LICENSE NSI-189 RIGHTS IN JAPAN NSI-189 currently in Phase I c
Read more →PALIMeg McElroy - Shareholder Relations 301.366.4960 Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330
Meg McElroy - Shareholder Relations 301.366.4960 Deanne Eagle - Media Relations 917.837.5866 Susan Roush - Investor Relations 818.222.8330 NEURALSTEM REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS AND CLINICAL UPDATE ROCKVILLE, Maryland, May 10, 2011-Neuralstem,
Read more →Competitive Position
How PALI ranks across every disease it competes inCompetitive Position is a premium feature
See how PALI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial